Question number,Question,Retrieved FileName,Chunk Text,Page Number,Position,Similarity
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,FMWSCPARDS.pdf," mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,  ICU-free days, and prevalence of acute kidney injury than FACTT Liberal. FACTT Lite can  be used as a simplified and safe alternative to FACTT Conservative for the management of  fluid balance in patients with ARDS. Supplementary Material Refer to Web version on PubMed Central for supplementary material. Acknowledgments Supported, in part, by the National Institutes of Health, National",8,76,0.8505194187164307
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,FMWSCPARDS.pdf," be easily understood and implemented by  physician and nursing staff in the ICU. Conclusions Although the FACTT Lite protocol had a greater cumulative fluid balance than FACTT  Conservative, the results of our study indicate that the FACTT Lite protocol is safe and has  equivalent ventilator-free days, ICU-free days, acute kidney injury, and adjusted 60-day  mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,",8,75,0.8505194187164307
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ETSDMV.pdf," [17,18,22,23]. The main side effects of  dexmedetomidine are bradycardia, hypotension and the potential for withdrawal symptoms  upon discontinuation of long-term therapy [17,18]. When compared to other sedatives,  dexmedetomidine has been shown to result in a more awake and interactive patient, a lower  incidence of delirium, more ventilator free days, and less days in the ICU [17–",3,26,0.8439829349517822
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,FMWSCPARDS.pdf,"; critical illness; fluid  therapy; shock Conservative fluid management improves ventilator-free days and oxygenation in patients  with the Acute Respiratory Distress Syndrome (ARDS). In the Fluid and Catheter Treatment  Trial (FACTT) of the National Institutes of Health, National Heart Lung and Blood Institute,  ARDS Network (NIH/NHLBI ARDS Network), patients were randomized and managed  with either a conservative fluid protocol (FACTT Conservative)",2,16,0.8276040554046631
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,SMDLTSWCI.pdf," 11, 14, 15]. Unlike other sedatives, dexmedetomidine—a highly  selective central alpha-2 adrenergic agonist with both  analgesic and sedative effects, notable for its ability to  provide light sedation, analgesia, and physiologic-like  sleep, as well as its minimal effect on respiratory drive— has been shown to result in a more awake and interactive  patient, a lower incidence of delirium, fewer days on ven- tilator",2,19,0.8245699405670166
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ENB.pdf," severe ARDS for its  short-term benefit in early phase of disease. Prolonged use of NMBAs beyond 48 hours requires further study. (Cite this article as: Lyu T, Lee YS, Dhanvijay S, Freebairn R. The effect of neuromuscular blocking agents uses in acute  respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Minerva Anestesiol  2021;87:341-",1,9,0.823427677154541
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ENB.pdf,"Vol. 87 - No. 3	 Minerva Anestesiologica	 341 R E V I E W The effect of neuromuscular blocking agents  uses in acute respiratory distress syndrome:  a systematic review and meta-analysis  of randomized controlled trials Ting LYU 1 *, Yee S. LEE 1, Shekhar DHANVIJAY 1, Ross FREEBAIRN 2 1Department of Intensive Care Medicine, Ng Teng Fong General Hospital,",1,1,0.823427677154541
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,DDS.pdf,"medetomidine in critically ill patients increased ventilator-free time [11] and decreased the incidence of postoperative complications, delirium, and mortality up to 1 year post-cardiac surgery [12]. In postoperative patients, dexmedetomidine provided sympatholytic ac- tivity [13]. It also offers anti-inflammatory and organ protective effects in animal models [14]. The use of dexmedetomidine as an anti-adrenergic strategy in se",1,6,0.8178668022155762
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,DDS.pdf," mediated by a blunted immune response, resulting in an improved microcirculation [7], or enhanced adrener- gic receptor sensitivity [8]. Dexmedetomidine is a highly selective alpha-2 adre- noreceptor agonist that has sedative, anxiolytic, and opioid-sparing effects (Table 2) [9, 10]. The use of dexmedetomidine in critically ill patients increased ventilator-free time [11] and decreased",1,5,0.8178668022155762
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ESCNBC.pdf," The  COVID-19 Critical Care Consortium  Abstract  Background:  The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute  respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients  with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS)",1,6,0.8158602714538574
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8104820251464844
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,ACURASYS.pdf," des Bourrely, 13009 Marseille, France, or  at laurent.papazian@ap-hm.fr. *The ARDS et Curarisation Systematique  (ACURASYS) study investigators are  listed in the Appendix. N Engl J Med 2010;363:1107-16. Copyright © 2010 Massachusetts Medical Society. Background In patients undergoing mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents",1,10,0.8104820251464844
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,TOF-ARDS.pdf,"/kg of predicted body weight  (PBW) [2], a short course of neuromuscular blocking  agents (NMBAs) [3] in severely hypoxemic patients, and  the use of prone positioning (PP) [4]. NMBAs are fre- quently used in the most severe forms of ARDS [1]. They  are the only pharmacologic intervention that has been  shown to improve the prognosis of moderate-to-severe  ARDS",1,12,0.8104820251464844
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,TOF-ARDS.pdf,"ourenne2 Abstract  Background:  Neuromuscular blocking agents (NMBAs) have been shown to improve the outcome of the most  severely hypoxemic, acute respiratory distress syndrome (ARDS) patients. However, the recommended dosage as  well as the necessity of monitoring the neuromuscular block is unknown. We aimed to evaluate the efficiency of a  nurse-directed protocol of NMBA administration based on a train-of-four (TOF) assessment",1,3,0.8104820251464844
1,Does early administration of neuromuscular blocking agents increases the ventilator free days?,HDDSICU.pdf,". Results showed that patients treated with dexmedetomidine experienced a comparable level of sedation, spent less time on the ventilator, experi- enced less delirium, and developed less tachycardia and hypertension.  Both the MENDS and SEDCOM trials used higher dexmedetomidine doses for longer durations than those previously studied and showed similar efficacy and safety outcomes.5,11 However, neither study assessed the impact of doses greater than 0.7",2,15,0.8028988838195801
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,LSPA.pdf,"–31 or  high PEEP strategies32,33 that are often employed for management of ARDS. However, deep  sedation is required in patients with ARDS who receive neuromuscular blockage to ensure  patients do not consciously experience paralysis.34,35 Neuromuscular blockage is sometimes  used in severe ARDS based on results of a multicenter trial in France that showed improved  mortality with 48 hours of neuromuscular blockage in patients who have severe",3,23,0.9385466575622559
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.8736917972564697
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8696675300598145
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,APV.pdf," ventilation variables have to be properly adjusted during ventilatory therapy, which generally requires continuous care from clinical staff, es- pecially for patients with severe ARDS. To minimize the workload of daily clinical practice and to maintain the standard protocol of protective ventilation, we introduce automatic control of ventilation as a concept for the treatment. In this article, we describe a strategy of auto- matic ventilation in ARDS patients, including continu- ous monitoring of regional ventilation at thoracic cavity using electrical impedance",2,18,0.8652796745300293
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8588335514068604
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,CEIIUPPSARDS.pdf, Setting: Intensive care units that care for patients with ARDS. Subjects: Patients with moderate to severe ARDS. For reprints : Corresponding Author: Cameron M Baston. 3400 Spruce St. Philadelphia PA 19104. cbass@alum.mit.edu  +12159133239.  The work was performed at the University of Pennsylvania Declaration of Conflict of Interest: The authors have disclosed that they do not have any conflicts of interest. HHS Public Access Author manuscript Crit,1,6,0.8582408428192139
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,EDPMARDSLPMV.pdf," this result may be due to the wide range of VT used across the trials included. To try to answer this question, we investigated ΔPrs from two trials [4, 5] in which strict lung- protective mechanical ventilation, in particular 6 ml/kg predicted body weight VT, was applied to patients with ARDS. Our working hypothesis was that ΔPrs was asso- ciated with death, just like compliance (Crs) or Pplat,rs. Methods This is a",2,18,0.8582408428192139
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,CEIIUPPSARDS.pdf,"ri F, Pugliese F, Ranieri VM. The Role of Rescue Therapies in the Treatment of Severe  ARDS. Respiratory care 2018;63(1):92–101. [PubMed: 29066591]  9. Li X, Scales DC, Kavanagh BP. Unproven and Expensive Before Proven and Cheap - Extracorporeal  Membrane Oxygenation vs. Prone Position in ARDS. American journal of",8,73,0.8507289886474609
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,ESCNBC.pdf,"Li Bassi et al. Critical Care          (2022) 26:141   https://doi.org/10.1186/s13054-022-03983-5 RESEARCH Early short course of neuromuscular  blocking agents in patients with COVID‑19  ARDS: a propensity score analysis Gianluigi Li Bassi1,2,",1,1,0.8477845191955566
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,APV.pdf," the formation of noncardiogenic pulmonary edema and inacti- vation of surfactant, leading to alveolar collapse and atelec- tasis. Progressive hypoxia and an increased work of breathing are then unavoidable. At the onset, ventilation support with mechanical ventilation is generally required. Since 2000, protective ventilation using the Acute Re- spiratory Distress Syndrome Network (ARDSNet) proto- col has continued to be the cornerstone in intensive care for ARDS therapy",2,14,0.8446857929229736
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8440487384796143
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,OSCILLATE.pdf,"DS.23-26 We therefore compared HFOV  with a conventional ventilation strategy that used  low tidal volumes and high levels of PEEP in pa- tients with new-onset, moderate-to-severe ARDS. Methods Study Oversight For the pilot phase of the study, we enrolled pa- tients at 11 centers in Canada and 1 in Saudi  Arabia from July 2007 through June 2008; for the  main trial, we enrolled patients at the same cen- ters",2,25,0.8414995670318604
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,PTARDS.pdf," 17). An important role for platelets in ARDS has also been described (12). This pivotal role for platelet activation in ARDS pathogenesis represents an oppor- tunity for a treatment strategy with ASA, and several studies, human and animal, have been undertaken testing the role of platelet inhibition in ARDS. We chose to study one specific antiplatelet agent in ARDS to produce a more homogeneous analysis. ASA is the most used and studied antiplatelet therapy, has",1,14,0.8398065567016602
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,PPATDSHMA.pdf,"occa, Milan, Italy c Department of Anesthesia and Intensive Care, Niguarda Hospital, Milan, Italy Received 7 August 2022; accepted 25 December 2022 Available online xxx Abstract Background: Researchers have tried unsuccessfully for many years using randomized controlled trials to show the efﬁcacy of prone ventilation in treating ARDS. These failed attempts were of use in designing the successful PROSEVA trial, published in 2013. However, the evidence provided by meta-analyses in",2,4,0.8398065567016602
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,NBSARDS.pdf," original ACURASYS trial13 re- sults in the decision to initiate NMB treatment in ARDS patients. We included 4 identically-worded questions ask- ing the respondents to grade the importance they placed on each of 4 potential justifications for starting NMB in pa- tients with moderate to severe ARDS. Based on a mean weighted score, the most important indication for initiating NMB in patients with moderate to severe ARDS was to allow compliance with ARDSNet mechanical ventilation",5,65,0.8339507579803467
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,ESCNBC.pdf,". Interna- tional studies have confirmed the use of NMBAs in up to  26% of ARDS patients [14]. Yet, conflicting results were  provided by large randomized clinical trials, such as the  ACURASYS [15] and ROSE trials [16], and indication,  efficacy, and safety on the use of NMBAs in such patients  remain uncertain. The severe respiratory failure associated with COVID- 19 has been described as a form of ARDS",2,20,0.8339507579803467
2,Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?,NBSARDS.pdf,"13 and ROSE trials,26 moderate to severe ARDS in the survey was de- fined as PaO2/FIO2  150 mm Hg, along with other Berlin criteria. The survey was approved by the University of Maryland School of Medicine Institutional Review Board. The survey writing team generated an initial 16-ques- tion survey that included 6 demographic questions, 3 ques- tions about whether the respondent managed patients with ARDS and whether they used NMB in their management",2,22,0.8296747207641602
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",LSPA.pdf,"–31 or  high PEEP strategies32,33 that are often employed for management of ARDS. However, deep  sedation is required in patients with ARDS who receive neuromuscular blockage to ensure  patients do not consciously experience paralysis.34,35 Neuromuscular blockage is sometimes  used in severe ARDS based on results of a multicenter trial in France that showed improved  mortality with 48 hours of neuromuscular blockage in patients who have severe",3,23,0.9309053421020508
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",RARDS.pdf," ARDSnet trials showed no difference between patients with moderate–severe and mild–moderate ARDS in terms of mortality, even though there were differences in rapid resolution of ARDS, ventilator-free days, and ICU-free days. Author disclosures are available with the text of this article at www.atsjournals.org. Acknowledgment: The authors are grateful to the investigators of ARDS Network (ARDSNet) trials for collecting the data on which this analysis was based,",3,42,0.8712306022644043
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8641161918640137
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.8626987934112549
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8527176380157471
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",BMIMSARDS.pdf,"Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial Haytham Tlayjeh, Yaseen M Arabi, Niall D Ferguson, Qi Zhou, Francois Lamontagne, Alejandro Arroliga, Valerie Danesh, Guillermo Dominguez-Cherit, Edgar Jimenez, Adam Mullaly, Brandon Staub, and Maureen O Meade; for the Canadian Critical Care Trials Group BACK",1,1,0.8506574630737305
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",TOF-ARDS.pdf,"/kg of predicted body weight  (PBW) [2], a short course of neuromuscular blocking  agents (NMBAs) [3] in severely hypoxemic patients, and  the use of prone positioning (PP) [4]. NMBAs are fre- quently used in the most severe forms of ARDS [1]. They  are the only pharmacologic intervention that has been  shown to improve the prognosis of moderate-to-severe  ARDS",1,12,0.8451581001281738
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8446910381317139
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",ESCNBC.pdf," The  COVID-19 Critical Care Consortium  Abstract  Background:  The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute  respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients  with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS)",1,6,0.8433651924133301
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",CEIIUPPSARDS.pdf,"ri F, Pugliese F, Ranieri VM. The Role of Rescue Therapies in the Treatment of Severe  ARDS. Respiratory care 2018;63(1):92–101. [PubMed: 29066591]  9. Li X, Scales DC, Kavanagh BP. Unproven and Expensive Before Proven and Cheap - Extracorporeal  Membrane Oxygenation vs. Prone Position in ARDS. American journal of",8,73,0.840766429901123
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",APV.pdf," ventilation variables have to be properly adjusted during ventilatory therapy, which generally requires continuous care from clinical staff, es- pecially for patients with severe ARDS. To minimize the workload of daily clinical practice and to maintain the standard protocol of protective ventilation, we introduce automatic control of ventilation as a concept for the treatment. In this article, we describe a strategy of auto- matic ventilation in ARDS patients, including continu- ous monitoring of regional ventilation at thoracic cavity using electrical impedance",2,18,0.838019847869873
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",ESCNBC.pdf,"Li Bassi et al. Critical Care          (2022) 26:141   https://doi.org/10.1186/s13054-022-03983-5 RESEARCH Early short course of neuromuscular  blocking agents in patients with COVID‑19  ARDS: a propensity score analysis Gianluigi Li Bassi1,2,",1,1,0.8326091766357422
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",OSCILLATE.pdf,"DS.23-26 We therefore compared HFOV  with a conventional ventilation strategy that used  low tidal volumes and high levels of PEEP in pa- tients with new-onset, moderate-to-severe ARDS. Methods Study Oversight For the pilot phase of the study, we enrolled pa- tients at 11 centers in Canada and 1 in Saudi  Arabia from July 2007 through June 2008; for the  main trial, we enrolled patients at the same cen- ters",2,25,0.8312351703643799
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",ESCPARDS.pdf,"prednisolone did not increase  the rate of infectious complications but was associated with a higher rate of neuro- muscular weakness. Conclusions These results do not support the routine use of methylprednisolone for persistent  ARDS despite the improvement in cardiopulmonary physiology. In addition, start- ing methylprednisolone therapy more than two weeks after the onset of ARDS may  increase the risk of death. (ClinicalTrials.gov number, NCT00295269",1,10,0.8305258750915527
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",EDPMARDSLPMV.pdf," this result may be due to the wide range of VT used across the trials included. To try to answer this question, we investigated ΔPrs from two trials [4, 5] in which strict lung- protective mechanical ventilation, in particular 6 ml/kg predicted body weight VT, was applied to patients with ARDS. Our working hypothesis was that ΔPrs was asso- ciated with death, just like compliance (Crs) or Pplat,rs. Methods This is a",2,18,0.8288090229034424
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",CEIIUPPSARDS.pdf, Setting: Intensive care units that care for patients with ARDS. Subjects: Patients with moderate to severe ARDS. For reprints : Corresponding Author: Cameron M Baston. 3400 Spruce St. Philadelphia PA 19104. cbass@alum.mit.edu  +12159133239.  The work was performed at the University of Pennsylvania Declaration of Conflict of Interest: The authors have disclosed that they do not have any conflicts of interest. HHS Public Access Author manuscript Crit,1,6,0.8288090229034424
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",PPATDSHMA.pdf," every time the PROSEVA study is excluded from a meta-analysis the p values for both effect and heterogeneity increase strikingly, whereas when other trials are omitted, they remain low with small variations. As shown in Table 2, the interaction test, which formally investigates the heterogeneity of effects across subgroups, was always signiﬁcant when the PROSEVA trial was compared with the rest of the studies. Discussion Prone ventilation is considered to be standard care for severe ARDS, and",4,40,0.8282098770141602
3,"In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?",NBSARDS.pdf,"13 and ROSE trials,26 moderate to severe ARDS in the survey was de- fined as PaO2/FIO2  150 mm Hg, along with other Berlin criteria. The survey was approved by the University of Maryland School of Medicine Institutional Review Board. The survey writing team generated an initial 16-ques- tion survey that included 6 demographic questions, 3 ques- tions about whether the respondent managed patients with ARDS and whether they used NMB in their management",2,22,0.8269100189208984
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,TOF-ARDS.pdf,"Hraiech et al. Ann. Intensive Care  (2017) 7:79  DOI 10.1186/s13613-017-0305-2 RESEARCH How to reduce cisatracurium  consumption in ARDS patients: the TOF‑ARDS  study Sami Hraiech1,3*, Jean‑Marie Forel1, Christophe Guervilly1, Romain Rambaud1, Samuel ",1,1,0.8267707824707031
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8246076107025146
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.8223733901977539
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,BMIMSARDS.pdf,"Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial Haytham Tlayjeh, Yaseen M Arabi, Niall D Ferguson, Qi Zhou, Francois Lamontagne, Alejandro Arroliga, Valerie Danesh, Guillermo Dominguez-Cherit, Edgar Jimenez, Adam Mullaly, Brandon Staub, and Maureen O Meade; for the Canadian Critical Care Trials Group BACK",1,1,0.8146486282348633
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8037803173065186
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8025448322296143
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,PPATDSHMA.pdf," every time the PROSEVA study is excluded from a meta-analysis the p values for both effect and heterogeneity increase strikingly, whereas when other trials are omitted, they remain low with small variations. As shown in Table 2, the interaction test, which formally investigates the heterogeneity of effects across subgroups, was always signiﬁcant when the PROSEVA trial was compared with the rest of the studies. Discussion Prone ventilation is considered to be standard care for severe ARDS, and",4,40,0.8012244701385498
4,Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who recieved an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?,NBSARDS.pdf,"13 and ROSE trials,26 moderate to severe ARDS in the survey was de- fined as PaO2/FIO2  150 mm Hg, along with other Berlin criteria. The survey was approved by the University of Maryland School of Medicine Institutional Review Board. The survey writing team generated an initial 16-ques- tion survey that included 6 demographic questions, 3 ques- tions about whether the respondent managed patients with ARDS and whether they used NMB in their management",2,22,0.8011879920959473
5,"Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?",FMWSCPARDS.pdf," mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,  ICU-free days, and prevalence of acute kidney injury than FACTT Liberal. FACTT Lite can  be used as a simplified and safe alternative to FACTT Conservative for the management of  fluid balance in patients with ARDS. Supplementary Material Refer to Web version on PubMed Central for supplementary material. Acknowledgments Supported, in part, by the National Institutes of Health, National",8,76,0.8423879146575928
5,"Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?",PAC-in-FACTT.pdf," AP, Bernard GR, Thompson  BT, Hayden D, deBoisblanc B, Connors AF, Jr., Hite  RD,  Harabin  AL:  Comparison  of  two  fluid- management strategies in acute lung injury. N Engl J  Med 2006, 354:2564-2575.    10.  Lemaire F: Suspension of the NIH ARDS Network  fluids and catheters treatment trial. Intensive Care  Med",3,37,0.8107426166534424
5,"Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?",RARDS.pdf," Comparison of two ﬂuid-management strategies in acute lung injury. N Engl J Med 2006;354:2564– 2575. 11 Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efﬁcacy and safety of corticosteroids for persistent acute respiratory distress syndrome",4,57,0.8107426166534424
5,"Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?",RARDS.pdf,"end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004;351:327–336. 10 Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two ﬂuid-management strategies in acute lung injury. N Engl J Med",4,56,0.8107426166534424
5,"Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?",DIHRFARDSNET.pdf,"–8. 10.1056/NEJM200005043421801. [6]. Comparison of Two Fluid-Management Strategies in Acute Lung Injury. New England Journal of  Medicine 2006;354:2564–75. 10.1056/NEJMoa062200. [7]. The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS)  Clinical Trials Network, Rice TW, Wheeler AP, Thompson BT, Steingrub",4,36,0.8105475902557373
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,FACTT.pdf," primary outcome of 60-day  mortality, the conservative strategy of fluid management improved lung function and  shortened the duration of mechanical ventilation and intensive care without in- creasing nonpulmonary-organ failures. These results support the use of a conserva- tive strategy of fluid management in patients with acute lung injury. (ClinicalTrials. gov number, NCT00281268.) The New England Journal of Medicine is produced by NEJM Group, a division of the Massachusetts Medical",1,11,0.8652496337890625
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,FMWSCPARDS.pdf,"; critical illness; fluid  therapy; shock Conservative fluid management improves ventilator-free days and oxygenation in patients  with the Acute Respiratory Distress Syndrome (ARDS). In the Fluid and Catheter Treatment  Trial (FACTT) of the National Institutes of Health, National Heart Lung and Blood Institute,  ARDS Network (NIH/NHLBI ARDS Network), patients were randomized and managed  with either a conservative fluid protocol (FACTT Conservative)",2,16,0.8584544658660889
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,RARDS.pdf," with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome (ARMA), Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress Syndrome (ALVEOLI), Comparison of Two Fluid-Management Strategies in Acute Lung Injury (FACTT), and Efﬁcacy and Safety of Corticosteroids for Persistent Acute",1,7,0.8471426963806152
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,ARDSSRDRFMS.pdf, What This Study Adds to the Field: We report the novel ﬁnding that ARDS subphenotypes as identiﬁed by latent class analysis have a differential response to randomly assigned ﬂuid management strategy. ARDS subphenotype could be identiﬁed with excellent accuracy using three variables in three distinct patient cohorts. ORIGINAL ARTICLE 332 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 3 | February 1 2017,2,34,0.8364853858947754
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,ARDSSRDRFMS.pdf,"subphenotypesintwoseparaterandomizedcontrolled trials with differential response to positive end-expiratory pressure. Objectives: To identify these subphenotypes in a third ARDS cohort, to test whether subphenotypes respond differently to ﬂuid management strategy, and to develop a practical model for subphenotype identiﬁcation. Methods: We used latent class analysis of baseline clinical and plasma biomarker data to identify subphenotypes in FACTT (Flu",1,4,0.8364853858947754
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,FMWSCPARDS.pdf,FACTT  Conservative) resulted in a lower cumulative fluid balance and better outcomes than a liberal fluid  protocol (FACTT Liberal). Subsequent Acute Respiratory Distress Syndrome Network studies  *See also p. 477 The members of the National Institutes of Health/National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome  Network are listed in Appendix 1. Institutions where this work was performed: Data analysis and article preparation were performed at Intermountain Medical Center,1,6,0.8300995826721191
6,Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?,FMWSCPARDS.pdf,"monary and Critical Care Medicine, Baystate Medical Center, Springfield, MA 9Respiratory Institute, Cleveland Clinic, Cleveland, OH 10Department of Anesthesiology, University of Maryland, Baltimore, MD Abstract Objectives—In the Fluid and Catheter Treatment Trial (FACTT) of the National Institutes of  Health Acute Respiratory Distress Syndrome Network, a conservative fluid protocol (FACTT  Conservative) resulted in a lower cumulative fluid balance and better outcomes than a liberal fluid",1,5,0.8300995826721191
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,EDPMARDSLPMV.pdf,"ôpitaux de Marseille Department of Research and Innovation Support Unit for clinical research and economic evaluation, Marseille 13005, France. Received: 17 August 2016 Accepted: 2 November 2016 References 1. ARDSnet. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301–8. 2. Amato",8,97,0.9633128643035889
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,RARDS.pdf," Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–1308. 9 Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher",3,52,0.9633128643035889
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,ARDSNet.pdf,"Volume 342 Number 18 · 1301 The New England Journal of Medicine © Copyright, 2000, by the Massachusetts Medical Society VOLUME 342 MAY 4, 2000 NUMBER 18 VENTILATION WITH LOWER TIDAL VOLUMES AS COMPARED WITH  TRADITIONAL TIDAL VOLUMES FOR ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK",1,1,0.9633128643035889
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,ENB.pdf,≤30  cm H20 AECC: American-European Consensus Conference; ARDS: Acute Respiratory Distress Syndrome; PaO2/FiO2: partial pressure of oxygen/ fractional inspired oxygen; PEEP: positive end expiratory pressure; TOF: train of four; ARDSnet protocol: ventilation with lower tidal  volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome; NO: nitric oxide; ,4,60,0.9630706310272217
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,"ere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med. 1994;149:1327–34. 22. Caironi P, Cressoni M, Chiumello D, Ranieri M, Quintel M, Russo SG, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2010;",3,42,0.9177660942077637
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,NBSARDS.pdf," J Med 2004;351(4):327-336. 22. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized con- trolled trial. JAMA 2008;299(6):637-645. 23. Mercat A, Richard JC",7,95,0.8895728588104248
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,ENB.pdf,"OSE trial  specifically mentioned the reason to use fixed  dose was to replicate the dosing regimen used  in the (ACURASYS) trial and to facilitate ad­ herence to the trial protocol.11, 15 All the studies  used lung protective ventilation with low tidal  volume with an aim of keeping plateau pres­ sure ≤30 cm H2O. It is also noted ACURASYS  and ROSE trials used one bolus NMDA per 24  hours in control group",4,52,0.8883187770843506
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf," medicine 2017:1–16. 12. Cooke CR, Kahn JM, Watkins TR, et al. Cost-effectiveness of implementing low-tidal volume  ventilation in patients with acute lung injury. CHEST Journal 2009;136(1):79–88. 13. Weiss CH, Baker DW, Tulas K, et al. A critical care clinician survey comparing attitudes and  perceived barriers to low tidal volume ventilation with actual practice. Annals of the American  Thoracic Society",8,76,0.8743646144866943
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf,"02]  7. Weiss CH, McSparron JI, Chatterjee RS, et al. Summary for Clinicians: Mechanical Ventilation in  Adult Patients with Acute Respiratory Distress Syndrome Clinical Practice Guideline. Ann Am  Thorac Soc 2017;14(8):1235–1238. [PubMed: 28763269]  8. Alessandri F, Pugliese F, Ranieri VM. The Role of Rescue Therapies in",8,72,0.8488991260528564
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,ARDSNet.pdf,VENTILATION WITH LOWER TIDAL VOLUMES IN PATIENTS WITH THE ACUTE RESPIRATORY DISTRESS SYNDROME Volume 342 Number 18 · 1305 incidence of barotrauma after randomization was sim- ilar in the two groups. There were no significant differences between groups in the percentages of days on which neuro- muscular-blocking drugs were used among patients who were discharged home and breathing without assistance (6±14 percent in the group treated with lower,5,69,0.8462350368499756
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,RARDS.pdf," Aerosolized b2-Agonist for Treatment of Acute Lung Injury (ALTA), Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury (EDEN), and Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome (SAILS) (5–7). For this analysis, we excluded individuals from the Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and",1,6,0.8458149433135986
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,ARDSSRDRFMS.pdf,", we used data from two randomized controlled trials (RCTs), ARMA and ALVEOLI (Assessment of Low tidal Volume and elevated End- expiratory volume to Obviate Lung Injury) (2, 4). Remarkably, these separate data- driven analyses identiﬁed two very similar subphenotypes in each trial. Subphenotype 2 was associated with increased levels of inﬂammatory biomarkers, acidosis, and shock and was",2,18,0.8426718711853027
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,LSPA.pdf,"individual patient data meta-analysis. Intensive care medicine. Jul; 2014 40(7):950–957. [PubMed:  24811940]  30. Kahn JM, Andersson L, Karir V, Polissar NL, Neff MJ, Rubenfeld GD. Low tidal volume  ventilation does not increase sedation use in patients with acute lung injury. Critical care medicine.  Apr; 2005 33(4):766–771. [PubMed",9,85,0.83512282371521
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,LSPA.pdf," of Chest Physicians and the American  Thoracic Society recommend using a sedation protocol to minimize sedation of  mechanically ventilated ICU patients.28 Balanced against the recommendation for light sedation is the occasional need for deep  sedation during advanced therapies for severe ARDS. A number of studies have shown that  deep sedation is not required for patients to tolerate the low tidal volume ventilation29–31 or  high PEEP strategies32,33 that are often employed for management of ARDS",3,22,0.83512282371521
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf," Tidal volume, driving pressure, flow, and respiratory rate have been identified as causes of ventilation-induced lung injury. Taken together, they represent the mechanical power applied to the lung parenchyma. In an inhomogeneous lung, stress risers locally increase the applied mechanical power. Increasing lung homogeneity by PEEP and prone position decreases the harm of mechanical ventilation, particularly in severe ARDS. Various etiologies can induce an inflammatory process in the lung parenchyma. In some",1,2,0.8348536491394043
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,". Intensive Care Med. 1990;16:372–7. 20. Chiumello D, Carlesso E, Cadringher P, Caironi P, Valenza F, Polli F, et al. Lung stress and strain during mechanical ventilation for acute respiratory distress syndrome. Am J Respir Crit Care Med. 2008;178:346–55. 21. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation",3,41,0.8340630531311035
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf,"]  5. Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of  Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical  Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. American journal of  respiratory and critical care medicine 2017;195(9):1253–1263. [PubMed: 28459336]  6. Bein T",8,70,0.8311862945556641
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf," assumptions. Keywords Respiratory Distress Syndrome; Adult; Cost-Benefit Analysis; Prone position; Economics;  Hospital; Decision Trees Introduction: Despite recent advances, survival following the acute respiratory distress syndrome (ARDS)  remains 50-60% in many settings (1–4). Prone positioning (PP) in moderate-severe ARDS  has been shown in randomized trials to substantially improve survival, and, like low-tidal- volume ventilation (LTV), is a",2,12,0.8289682865142822
7,Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,", Blanch L, Murias G, Adams AB, Olson DA, Wangensteen OD, et al. Effects of decreased respiratory frequency on ventilator-induced lung injury. Am J Respir Crit Care Med. 2000;161(2 Pt 1):463–8. 28. Fujita Y, Fujino Y, Uchiyama A, Mashimo T, Nishimura M. High peak inspiratory flow can aggravate ventilator-induced lung injury in rabbits. Med",3,46,0.824648380279541
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,EDPMARDSLPMV.pdf,"ôpitaux de Marseille Department of Research and Innovation Support Unit for clinical research and economic evaluation, Marseille 13005, France. Received: 17 August 2016 Accepted: 2 November 2016 References 1. ARDSnet. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301–8. 2. Amato",8,97,0.9403524398803711
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ARDSNet.pdf,"Volume 342 Number 18 · 1301 The New England Journal of Medicine © Copyright, 2000, by the Massachusetts Medical Society VOLUME 342 MAY 4, 2000 NUMBER 18 VENTILATION WITH LOWER TIDAL VOLUMES AS COMPARED WITH  TRADITIONAL TIDAL VOLUMES FOR ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK",1,1,0.9403524398803711
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,RARDS.pdf," Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–1308. 9 Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher",3,52,0.9403524398803711
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ENB.pdf,≤30  cm H20 AECC: American-European Consensus Conference; ARDS: Acute Respiratory Distress Syndrome; PaO2/FiO2: partial pressure of oxygen/ fractional inspired oxygen; PEEP: positive end expiratory pressure; TOF: train of four; ARDSnet protocol: ventilation with lower tidal  volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome; NO: nitric oxide; ,4,60,0.9402601718902588
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,"ere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med. 1994;149:1327–34. 22. Caironi P, Cressoni M, Chiumello D, Ranieri M, Quintel M, Russo SG, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2010;",3,42,0.8957417011260986
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,NBSARDS.pdf," J Med 2004;351(4):327-336. 22. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized con- trolled trial. JAMA 2008;299(6):637-645. 23. Mercat A, Richard JC",7,95,0.87813401222229
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf," medicine 2017:1–16. 12. Cooke CR, Kahn JM, Watkins TR, et al. Cost-effectiveness of implementing low-tidal volume  ventilation in patients with acute lung injury. CHEST Journal 2009;136(1):79–88. 13. Weiss CH, Baker DW, Tulas K, et al. A critical care clinician survey comparing attitudes and  perceived barriers to low tidal volume ventilation with actual practice. Annals of the American  Thoracic Society",8,76,0.8661749362945557
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ENB.pdf,"OSE trial  specifically mentioned the reason to use fixed  dose was to replicate the dosing regimen used  in the (ACURASYS) trial and to facilitate ad­ herence to the trial protocol.11, 15 All the studies  used lung protective ventilation with low tidal  volume with an aim of keeping plateau pres­ sure ≤30 cm H2O. It is also noted ACURASYS  and ROSE trials used one bolus NMDA per 24  hours in control group",4,52,0.8550364971160889
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf,"02]  7. Weiss CH, McSparron JI, Chatterjee RS, et al. Summary for Clinicians: Mechanical Ventilation in  Adult Patients with Acute Respiratory Distress Syndrome Clinical Practice Guideline. Ann Am  Thorac Soc 2017;14(8):1235–1238. [PubMed: 28763269]  8. Alessandri F, Pugliese F, Ranieri VM. The Role of Rescue Therapies in",8,72,0.8476173877716064
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,", Blanch L, Murias G, Adams AB, Olson DA, Wangensteen OD, et al. Effects of decreased respiratory frequency on ventilator-induced lung injury. Am J Respir Crit Care Med. 2000;161(2 Pt 1):463–8. 28. Fujita Y, Fujino Y, Uchiyama A, Mashimo T, Nishimura M. High peak inspiratory flow can aggravate ventilator-induced lung injury in rabbits. Med",3,46,0.837775468826294
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ETSDMV.pdf,"▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to prevent ICU delirium. Notable for being one of the few interventions shown  to prevent ICU delirium. 30. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and  ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmed",8,82,0.8358793258666992
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,CEIIUPPSARDS.pdf,"]  5. Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of  Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical  Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. American journal of  respiratory and critical care medicine 2017;195(9):1253–1263. [PubMed: 28459336]  6. Bein T",8,70,0.8279781341552734
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,LSPA.pdf," Mehta S, Cook DJ, Skrobik Y, et al. A ventilator strategy combining low tidal volume ventilation,  recruitment maneuvers, and high positive end-expiratory pressure does not increase sedative,  opioid, or neuromuscular blocker use in adults with acute respiratory distress syndrome and may  improve patient comfort. Annals of intensive care. 2014; 4:33. [PubMed: 25593749]  34. Bein T, Grasso",9,88,0.8270058631896973
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ARDSSRDRFMS.pdf,", we used data from two randomized controlled trials (RCTs), ARMA and ALVEOLI (Assessment of Low tidal Volume and elevated End- expiratory volume to Obviate Lung Injury) (2, 4). Remarkably, these separate data- driven analyses identiﬁed two very similar subphenotypes in each trial. Subphenotype 2 was associated with increased levels of inﬂammatory biomarkers, acidosis, and shock and was",2,18,0.8233542442321777
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf," Tidal volume, driving pressure, flow, and respiratory rate have been identified as causes of ventilation-induced lung injury. Taken together, they represent the mechanical power applied to the lung parenchyma. In an inhomogeneous lung, stress risers locally increase the applied mechanical power. Increasing lung homogeneity by PEEP and prone position decreases the harm of mechanical ventilation, particularly in severe ARDS. Various etiologies can induce an inflammatory process in the lung parenchyma. In some",1,2,0.8206479549407959
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,HARDST.pdf,". Intensive Care Med. 1990;16:372–7. 20. Chiumello D, Carlesso E, Cadringher P, Caironi P, Valenza F, Polli F, et al. Lung stress and strain during mechanical ventilation for acute respiratory distress syndrome. Am J Respir Crit Care Med. 2008;178:346–55. 21. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation",3,41,0.8187897205352783
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,PPATDSHMA.pdf," J Thorac Dis. 2015;7(3):35667. https://doi.org/10.3978/j. issn.2072-1439.2014.12.49. 16. Mora-Arteaga JA, Bernal-Ramirez OJ, Rodriguez SJ. The effects of prone position ventilation in patients with acute respiratory distress syndrome. A systematic review and metaanalysis. Medicina Intensiva. 2015;39(6):35972",8,97,0.8143062591552734
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,FMWSCPARDS.pdf,"; critical illness; fluid  therapy; shock Conservative fluid management improves ventilator-free days and oxygenation in patients  with the Acute Respiratory Distress Syndrome (ARDS). In the Fluid and Catheter Treatment  Trial (FACTT) of the National Institutes of Health, National Heart Lung and Blood Institute,  ARDS Network (NIH/NHLBI ARDS Network), patients were randomized and managed  with either a conservative fluid protocol (FACTT Conservative)",2,16,0.8135685920715332
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ETSDMV.pdf," [17,18,22,23]. The main side effects of  dexmedetomidine are bradycardia, hypotension and the potential for withdrawal symptoms  upon discontinuation of long-term therapy [17,18]. When compared to other sedatives,  dexmedetomidine has been shown to result in a more awake and interactive patient, a lower  incidence of delirium, more ventilator free days, and less days in the ICU [17–",3,26,0.8133223056793213
8,Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?,ENB.pdf," The benefit of NMBAs use in ARDS was well  recognized. It can reduce ventilator-induced lung  injury by improving patient-ventilator synchro­ ny; reduce oxygen consumption and possible  indirect anti-inflammatory effects.10, 19, 20 Animal  studies showed that NMBA use in ARDS can re­ duce cytokine release such as plasma tumor ne­ crosis factor (TNF)-α level and interleukin (IL)- 6",5,65,0.8128318786621094
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,CEIIUPPSARDS.pdf," cohort study. The Lancet Respiratory Medicine 2017;5(8):627–638. [PubMed:  28624388]  11. Guérin C, Beuret P, Constantin J, et al. A prospective international observational prevalence study  on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study.  Intensive care medicine 2017:1–16. 12. Cooke CR, Kahn JM, Watkins TR, et al",8,75,0.9439983367919922
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,RARDS.pdf," ARDSnet trials showed no difference between patients with moderate–severe and mild–moderate ARDS in terms of mortality, even though there were differences in rapid resolution of ARDS, ventilator-free days, and ICU-free days. Author disclosures are available with the text of this article at www.atsjournals.org. Acknowledgment: The authors are grateful to the investigators of ARDS Network (ARDSNet) trials for collecting the data on which this analysis was based,",3,42,0.8686232566833496
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8684015274047852
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.8673136234283447
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,BMIMSARDS.pdf,"Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial Haytham Tlayjeh, Yaseen M Arabi, Niall D Ferguson, Qi Zhou, Francois Lamontagne, Alejandro Arroliga, Valerie Danesh, Guillermo Dominguez-Cherit, Edgar Jimenez, Adam Mullaly, Brandon Staub, and Maureen O Meade; for the Canadian Critical Care Trials Group BACK",1,1,0.8664274215698242
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,EDPMARDSLPMV.pdf," this result may be due to the wide range of VT used across the trials included. To try to answer this question, we investigated ΔPrs from two trials [4, 5] in which strict lung- protective mechanical ventilation, in particular 6 ml/kg predicted body weight VT, was applied to patients with ARDS. Our working hypothesis was that ΔPrs was asso- ciated with death, just like compliance (Crs) or Pplat,rs. Methods This is a",2,18,0.85994553565979
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,CEIIUPPSARDS.pdf, Setting: Intensive care units that care for patients with ARDS. Subjects: Patients with moderate to severe ARDS. For reprints : Corresponding Author: Cameron M Baston. 3400 Spruce St. Philadelphia PA 19104. cbass@alum.mit.edu  +12159133239.  The work was performed at the University of Pennsylvania Declaration of Conflict of Interest: The authors have disclosed that they do not have any conflicts of interest. HHS Public Access Author manuscript Crit,1,6,0.85994553565979
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,APV.pdf," ventilation variables have to be properly adjusted during ventilatory therapy, which generally requires continuous care from clinical staff, es- pecially for patients with severe ARDS. To minimize the workload of daily clinical practice and to maintain the standard protocol of protective ventilation, we introduce automatic control of ventilation as a concept for the treatment. In this article, we describe a strategy of auto- matic ventilation in ARDS patients, including continu- ous monitoring of regional ventilation at thoracic cavity using electrical impedance",2,18,0.8582706451416016
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8541696071624756
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,LSPA.pdf,"–31 or  high PEEP strategies32,33 that are often employed for management of ARDS. However, deep  sedation is required in patients with ARDS who receive neuromuscular blockage to ensure  patients do not consciously experience paralysis.34,35 Neuromuscular blockage is sometimes  used in severe ARDS based on results of a multicenter trial in France that showed improved  mortality with 48 hours of neuromuscular blockage in patients who have severe",3,23,0.8476228713989258
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8450167179107666
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,TOF-ARDS.pdf,"/kg of predicted body weight  (PBW) [2], a short course of neuromuscular blocking  agents (NMBAs) [3] in severely hypoxemic patients, and  the use of prone positioning (PP) [4]. NMBAs are fre- quently used in the most severe forms of ARDS [1]. They  are the only pharmacologic intervention that has been  shown to improve the prognosis of moderate-to-severe  ARDS",1,12,0.8403716087341309
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,NBSARDS.pdf," original ACURASYS trial13 re- sults in the decision to initiate NMB treatment in ARDS patients. We included 4 identically-worded questions ask- ing the respondents to grade the importance they placed on each of 4 potential justifications for starting NMB in pa- tients with moderate to severe ARDS. Based on a mean weighted score, the most important indication for initiating NMB in patients with moderate to severe ARDS was to allow compliance with ARDSNet mechanical ventilation",5,65,0.8384449481964111
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,ESCNBC.pdf,". Interna- tional studies have confirmed the use of NMBAs in up to  26% of ARDS patients [14]. Yet, conflicting results were  provided by large randomized clinical trials, such as the  ACURASYS [15] and ROSE trials [16], and indication,  efficacy, and safety on the use of NMBAs in such patients  remain uncertain. The severe respiratory failure associated with COVID- 19 has been described as a form of ARDS",2,20,0.8384449481964111
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,FMWSCPARDS.pdf," mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,  ICU-free days, and prevalence of acute kidney injury than FACTT Liberal. FACTT Lite can  be used as a simplified and safe alternative to FACTT Conservative for the management of  fluid balance in patients with ARDS. Supplementary Material Refer to Web version on PubMed Central for supplementary material. Acknowledgments Supported, in part, by the National Institutes of Health, National",8,76,0.8290410041809082
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,BMIMSARDS.pdf," THE RELATED EDITORIAL ON PAGE 1173 12 mL/kg did not show any difference in outcome between obese and normal weight subjects.7 Other studies have suggested better survival for obese subjects with ARDS compared to subjects with normal weight.5 Studies have also shown that being underweight is associated with in- creased mortality in subjects with ARDS.8 The Oscillation for ARDS Treated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate",2,15,0.8264801502227783
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,BMIMSARDS.pdf," associations at both extremes of BMI. Conclusions In the OSCILLATE Trial, there was no difference in adjusted hospital mortality across all BMI strata in sub- jects with moderate-to-severe ARDS. Processes of care were not different between the BMI strata except for higher daily doses of fentanyl as BMI increased. ACKNOWLEDGMENTS We acknowledge Michael Chasse and Martin Albert for their critical review of the manuscript. REFERENCES 1. Ogden CL,",7,92,0.8250975608825684
9,Prone positioning sessions in patients with severe ARDS significantly decreased mortality?,BMIMSARDS.pdf,". It also includes subjects managed with HFOV, a group in which the relation of BMI and outcomes has not been studied before. Methods Study Subjects and Sample The OSCILLATE trial randomized 548 subjects with moderate-to-severe ARDS to HFOV or conventional ven- tilation from 39 ICUs in Canada, the United States, Saudi Arabia, Chile, and India.9 Institutional review boards of the participating centers approved the study. Patients were eligible for inclusion if they had",2,18,0.8250975608825684
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,OSCILLATE.pdf," other reasons 23 Did not undergo randomization 19 Had Pao2:FIo2 ratio >200 mm Hg  on standard settings 4 Had other reasons Figure 1. Screening, Randomization, and Follow-up. HFOV denotes high-frequency oscillatory ventilation, ICU intensive care unit, and Pao2:Fio2 the ratio of the partial  pressure of arterial oxygen to the fraction of inspired oxygen. The New England Journal of Medicine is produced by NEJM Group",6,81,0.8774561882019043
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,CEIIUPPSARDS.pdf," assumptions. Keywords Respiratory Distress Syndrome; Adult; Cost-Benefit Analysis; Prone position; Economics;  Hospital; Decision Trees Introduction: Despite recent advances, survival following the acute respiratory distress syndrome (ARDS)  remains 50-60% in many settings (1–4). Prone positioning (PP) in moderate-severe ARDS  has been shown in randomized trials to substantially improve survival, and, like low-tidal- volume ventilation (LTV), is a",2,12,0.8748822212219238
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,LSPA.pdf,"individual patient data meta-analysis. Intensive care medicine. Jul; 2014 40(7):950–957. [PubMed:  24811940]  30. Kahn JM, Andersson L, Karir V, Polissar NL, Neff MJ, Rubenfeld GD. Low tidal volume  ventilation does not increase sedation use in patients with acute lung injury. Critical care medicine.  Apr; 2005 33(4):766–771. [PubMed",9,85,0.8705143928527832
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,LSPA.pdf," of Chest Physicians and the American  Thoracic Society recommend using a sedation protocol to minimize sedation of  mechanically ventilated ICU patients.28 Balanced against the recommendation for light sedation is the occasional need for deep  sedation during advanced therapies for severe ARDS. A number of studies have shown that  deep sedation is not required for patients to tolerate the low tidal volume ventilation29–31 or  high PEEP strategies32,33 that are often employed for management of ARDS",3,22,0.8705143928527832
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,RARDS.pdf," Aerosolized b2-Agonist for Treatment of Acute Lung Injury (ALTA), Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury (EDEN), and Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome (SAILS) (5–7). For this analysis, we excluded individuals from the Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and",1,6,0.8685815334320068
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,ARDSNet.pdf,VENTILATION WITH LOWER TIDAL VOLUMES IN PATIENTS WITH THE ACUTE RESPIRATORY DISTRESS SYNDROME Volume 342 Number 18 · 1305 incidence of barotrauma after randomization was sim- ilar in the two groups. There were no significant differences between groups in the percentages of days on which neuro- muscular-blocking drugs were used among patients who were discharged home and breathing without assistance (6±14 percent in the group treated with lower,5,69,0.8685269355773926
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,CEIIUPPSARDS.pdf," barriers to low tidal volume ventilation with actual practice. Annals of the American  Thoracic Society 2017;14(11):1682–1689. [PubMed: 28771042]  14. Abrams D, Fan E, Ferguson ND, et al. Unproven and Expensive May Still Be Justifiable. American  journal of respiratory and critical care medicine 2018(ja). 15. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct",8,77,0.8668146133422852
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,HARDST.pdf,". Intensive Care Med. 1990;16:372–7. 20. Chiumello D, Carlesso E, Cadringher P, Caironi P, Valenza F, Polli F, et al. Lung stress and strain during mechanical ventilation for acute respiratory distress syndrome. Am J Respir Crit Care Med. 2008;178:346–55. 21. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation",3,41,0.8643131256103516
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,BMIMSARDS.pdf,"ated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate-to-severe ARDS to high-frequency oscillatory ventilation (HFOV) or conventional mechani- cal ventilation. The purpose of this sub-analysis of the OSCILLATE trial was to examine the association of BMI on mortality and relevant processes of care of subjects withmoderate-to-severeARDS.Wehypothesizedthatmor- tality differs across different BMI strata and",2,16,0.8521647453308105
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,ENB.pdf,"OSE trial  specifically mentioned the reason to use fixed  dose was to replicate the dosing regimen used  in the (ACURASYS) trial and to facilitate ad­ herence to the trial protocol.11, 15 All the studies  used lung protective ventilation with low tidal  volume with an aim of keeping plateau pres­ sure ≤30 cm H2O. It is also noted ACURASYS  and ROSE trials used one bolus NMDA per 24  hours in control group",4,52,0.851600170135498
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,CEIIUPPSARDS.pdf," medicine 2017:1–16. 12. Cooke CR, Kahn JM, Watkins TR, et al. Cost-effectiveness of implementing low-tidal volume  ventilation in patients with acute lung injury. CHEST Journal 2009;136(1):79–88. 13. Weiss CH, Baker DW, Tulas K, et al. A critical care clinician survey comparing attitudes and  perceived barriers to low tidal volume ventilation with actual practice. Annals of the American  Thoracic Society",8,76,0.8417932987213135
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,RARDS.pdf," Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–1308. 9 Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher",3,52,0.8356211185455322
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,EDPMARDSLPMV.pdf,"ôpitaux de Marseille Department of Research and Innovation Support Unit for clinical research and economic evaluation, Marseille 13005, France. Received: 17 August 2016 Accepted: 2 November 2016 References 1. ARDSnet. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301–8. 2. Amato",8,97,0.8356211185455322
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,ARDSNet.pdf,"Volume 342 Number 18 · 1301 The New England Journal of Medicine © Copyright, 2000, by the Massachusetts Medical Society VOLUME 342 MAY 4, 2000 NUMBER 18 VENTILATION WITH LOWER TIDAL VOLUMES AS COMPARED WITH  TRADITIONAL TIDAL VOLUMES FOR ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK",1,1,0.8356211185455322
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,ENB.pdf,≤30  cm H20 AECC: American-European Consensus Conference; ARDS: Acute Respiratory Distress Syndrome; PaO2/FiO2: partial pressure of oxygen/ fractional inspired oxygen; PEEP: positive end expiratory pressure; TOF: train of four; ARDSnet protocol: ventilation with lower tidal  volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome; NO: nitric oxide; ,4,60,0.8355016708374023
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,HARDST.pdf,"ere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med. 1994;149:1327–34. 22. Caironi P, Cressoni M, Chiumello D, Ranieri M, Quintel M, Russo SG, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2010;",3,42,0.8281264305114746
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,LSPA.pdf,"seizure, alcohol or benzodiazepine withdrawal, or to ensure deep sedation and amnesia (e.g.,  during paralysis). Recent studies have confirmed that the use of benzodiazepines for  sedation in critically ill patients is associated with increased delirium, increased hospital  length of stay, increased time on mechanical ventilation, and increased intensive care unit  hospitalization.2,52–54 A recent propensity-based analysis also suggested that  benzodiazepine use",5,38,0.8226113319396973
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,DDMLSMVICP.pdf,"EDCOM (Safety and Efﬁcacy of Dexmedetomidine Compared With Midazolam) Study Group D elirium is a recognized organ dysfunction complicating critical illness and consti- tutes a major challenge to in- tensive care practitioners worldwide (1– 3). In a survey of critical care clinicians, 85% of responders perceived intensive care unit (ICU) delirium as a signiﬁcant factor in prolonged ventilation",1,2,0.8213117122650146
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,PPATDSHMA.pdf," PROSEVA trial, published in 2013. However, the evidence provided by meta-analyses in support of prone ventilation for ARDS was too low to be conclusive. The pres- ent study shows that meta-analysis is indeed not the best approach for the assessment of evi- dence as to the efﬁcacy of prone ventilation. Methods: We performed a cumulative meta-analysis to prove that only the PROSEVA trial, due to its strong protective effect, has",2,5,0.8164489269256592
10,Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?,ETSDMV.pdf," a nonbenzodiazepine  sedative such as dexmedetomidine or propofol should be used if sedation is needed, though  analgesia alone may be adequate. When sedation is administered, a light level of sedation  should be targeted utilizing daily interruptions of sedation or nursing protocols with  validated sedations scales. Avoiding benzodiazepines and deep sedation results in less  delirium, shorter duration of mechanical ventilation, and improved mortality.",6,53,0.8156204223632812
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",ADRENAL.pdf,"RENAL) trial to test the hypoth- esis that hydrocortisone results in lower mortality  than placebo among patients with septic shock.17 Methods Trial Design and Oversight Our trial was an investigator-initiated, interna- tional, pragmatic, double-blind, parallel-group,  randomized, controlled trial that compared intra- venous infusions of hydrocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation",2,21,0.9326992034912109
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",ANNANE.pdf,"CARING FOR THE CRITICALLY ILL PATIENT Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock Djillali Annane, MD, PhD Ve´ronique Se´bille, PhD Claire Charpentier, MD Pierre-Edouard Bollaert, MD, PhD Bruno Franc¸ois, MD Jean-Michel Korach, MD Gilles Capellier, MD",1,1,0.9206202030181885
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",CORTICUS.pdf,"n engl j med 358;2  www.nejm.org  january 10, 2008 111 The new england   journal of medicine established in 1812	 january 10, 2008	 vol. 358  no. 2 Hydrocortisone Therapy for Patients with Septic Shock Charles L. Sprung, M.D., Djillali Annane, M.D., Ph.D., Didier Keh, M.D., Rui",1,1,0.9081733226776123
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",HYPRESS.pdf," the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use only in patients with inadequate response to fluid and vasopressor resuscitation.2 However, septic shock rever- sal in the CORTICUS study was reported to be significantly ac- celerated by the administration of hydrocortisone irrespec- tive of the adrenal response to corticotropin. An international consensus statement recommended replacing the terms rela- tive",2,19,0.8993539810180664
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",HYPRESS.pdf," 2 randomized clinical trials (RCTs).2 In the study by Annane et al,3 hydro- cortisone improved survival and reversal of septic shock in pa- tients with relative adrenal insufficiency. In the CORTICUS study,4 septic shock was reversed more quickly but mortality was not significantly reduced. The higher risk of mortality and septic shock severity in the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use",2,18,0.8987545967102051
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",PLMALDHSS.pdf,"ORIGINAL ARTICLE Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock Romain Pirracchio, M.D., M.P.H., Ph.D.,1,* Djillali Annane, M.D., Ph.D.,2,3,4,* Andre K. Waschka, Ph.D.,5,6 François Lamontagne, M.D., M.Sc.,7,8",1,1,0.8963584899902344
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",HYPRESS.pdf,"ortisone to prevent progression to shock in patients with severe sepsis presenting without shock. Methods Study Design The Hydrocortisone for Prevention of Septic Shock (HYPRESS) study is an investigator-initiated, multicenter, placebo- controlled, double-blind RCT supported by the German Fed- eral Ministry of Education and Research. The study was con- ducted in cooperation with the German Sepsis Competence Network (SepNet) and the Clinical Trial Centre Le",2,23,0.8924069404602051
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",APROCCHSS.pdf," istry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209.) ABSTR ACT Hydrocortisone plus Fludrocortisone   for Adults with Septic Shock D. Annane, A. Renault, C. Brun‑Buisson, B. Megarbane, J.-P. Quenot, S. Siami,  A. Cariou, X. Forceville, C. Schwebel, C",1,13,0.8843693733215332
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",HYPRESS.pdf,"Copyright 2016 American Medical Association. All rights reserved. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis The HYPRESS Randomized Clinical Trial Didier Keh, MD; Evelyn Trips; Gernot Marx, MD; Stefan P. Wirtz, MD; Emad Abduljawwad, MD; Sven Bercker, MD; Holger Bogatsch, MD; Josef Briegel, MD; Christoph Engel, MD",1,1,0.8812880516052246
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",APROCCHSS.pdf," hydrocortisone plus fludrocortisone. There  was some imbalance between the two groups  in the distribution of pathogens, with slightly  more viral infections in the hydrocortisone-plus- fludrocortisone group than in the placebo group. The mechanisms by which corticosteroids may  favorably affect the outcome of patients with  septic shock have been detailed recently.7 In  brief, corticosteroids improve cardiovascular func- tion by restoring",7,97,0.8505392074584961
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",APROCCHSS.pdf,"isone or with drotrecogin alfa (activated), which can modulate  the host response, would improve the clinical outcomes of patients with septic shock. METHODS In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we  evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (ac- tivated), the combination of the three",1,4,0.8501431941986084
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",TRISS.pdf," Septic Shock (TRISS)  trial to evaluate the effects on mortality of leuko- reduced blood transfusion at a lower versus a  higher hemoglobin threshold among patients  with septic shock who are in the intensive care  unit (ICU). METHODS TRIAL DESIGN AND OVERSIGHT After the approvals from ethics committees and  data-protection agencies were obtained, patients in  32 general ICUs in Denmark, Sweden, Norway, and  Finland underwent screening and randomization",2,28,0.8402061462402344
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",SS3vsSS2.pdf," we reanalyzed the results from the ALBIOS study [1] - which in 2014 compared the efficacy of the administration of albumin and crystalloids versus crystalloids alone in patients with septic shock - based on the new definition of septic shock. Our aim was to report differences in the populations classified as Shock-2 or Shock-3, highlighting possible advantages and disadvan- tages of this new definition. Methods This study was a retrospective analysis of data from the ALBIOS",2,19,0.8402061462402344
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",ADRENAL.pdf,"rocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation in an inten- sive care unit (ICU). We conducted the trial in  Australia, the United Kingdom, New Zealand,  Saudi Arabia, and Denmark. The trial management committee designed the  trial. The trial sponsor (the George Institute for  Global Health, Australia) coordinated all the  operational processes and conducted all the sta- tistical analyses. Trained research coordinators",2,22,0.8402061462402344
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",FRESHS.pdf," this randomized controlled trial, we evaluated the efﬁcacy of dynamic measures (stroke volume change during passive leg raise) to guide resuscitation and improve patient outcome. RESEARCH QUESTION: Will resuscitation that is guided by dynamic assessments of ﬂuid responsiveness in patients with septic shock improve patient outcomes? STUDY DESIGN AND METHODS: We conducted a prospective, multicenter, randomized clinical trial at 13 hospitals in the United States and United Kingdom. Patients presented",1,3,0.8402061462402344
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",ADRENAL.pdf,".) abstr act Adjunctive Glucocorticoid Therapy in Patients   with Septic Shock B. Venkatesh, S. Finfer, J. Cohen, D. Rajbhandari, Y. Arabi, R. Bellomo, L. Billot, M. Correa, P. Glass,   M. Harward, C. Joyce, Q. Li, C. McArthur, A. Perner, A. Rhodes, K.",1,12,0.8374862670898438
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",SS3vsSS2.pdf," infusion in patients with septic shock. N Engl J Med. 2008; 358:877–87. 13. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:775–87. 14. Rivers E, Nguyen B, Havstad S",7,94,0.836061954498291
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",SS3vsSS2.pdf," in 100 intensive care units in Italy comparing the administration of 20% albumin and crystalloids versus crystalloids alone in patients with severe sepsis or septic shock. We analyzed data from 1741 patients from ALBIOS with serum lactate measurement available at baseline. We compared group size, physiological variables and 90-day mortality between patients defined by Shock-2 and Shock-3 and between the albumin and crystalloid treatment groups. Results: We compared the Shock-2 and the Shock-",1,4,0.834632396697998
11,"Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?",SS3vsSS2.pdf," degli Studi di Milano, Milan, Italy. 9University of Milan-Bicocca, School of Medicine and Surgery, Monza, Italy. Table 3 Enrolment rate of septic shock patients in recent randomized controlled trials on sepsis Study TRISS [5] SEPSISPAM [6] ProCESS [7] ARISE [8] ALBIOS [1] VASST [12] Patients enrolled (n) 1005 776 13",6,83,0.832937479019165
12,Does a 7-day treatment with low doses of steriods significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?,ANNANE.pdf,"CARING FOR THE CRITICALLY ILL PATIENT Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock Djillali Annane, MD, PhD Ve´ronique Se´bille, PhD Claire Charpentier, MD Pierre-Edouard Bollaert, MD, PhD Bruno Franc¸ois, MD Jean-Michel Korach, MD Gilles Capellier, MD",1,1,0.8141734600067139
12,Does a 7-day treatment with low doses of steriods significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?,ADRENAL.pdf,"RENAL) trial to test the hypoth- esis that hydrocortisone results in lower mortality  than placebo among patients with septic shock.17 Methods Trial Design and Oversight Our trial was an investigator-initiated, interna- tional, pragmatic, double-blind, parallel-group,  randomized, controlled trial that compared intra- venous infusions of hydrocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation",2,21,0.8136601448059082
12,Does a 7-day treatment with low doses of steriods significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?,PLMALDHSS.pdf," Central Register of Controlled Trials (CENTRAL; 2020 Issue 9) MEDLINE ALL (Ovid SP), Embase (Ovid SP), and Latin American Caribbean Health Sciences Literature (LILACS) using the search terms “sepsis,” “septic shock,” “steroids,” and “corticosteroids.” The electronic search was completed in September 2020. The search of the gray literature (i.e., material",2,26,0.8074803352355957
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,ADRENAL.pdf,"RENAL) trial to test the hypoth- esis that hydrocortisone results in lower mortality  than placebo among patients with septic shock.17 Methods Trial Design and Oversight Our trial was an investigator-initiated, interna- tional, pragmatic, double-blind, parallel-group,  randomized, controlled trial that compared intra- venous infusions of hydrocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation",2,21,0.831479549407959
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf," hydrocortisone plus fludrocortisone. There  was some imbalance between the two groups  in the distribution of pathogens, with slightly  more viral infections in the hydrocortisone-plus- fludrocortisone group than in the placebo group. The mechanisms by which corticosteroids may  favorably affect the outcome of patients with  septic shock have been detailed recently.7 In  brief, corticosteroids improve cardiovascular func- tion by restoring",7,97,0.8290078639984131
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf,"ortisone-plus-fludrocortisone group. CONCLUSIONS In this trial involving patients with septic shock, 90-day all-cause mortality was lower among  those who received hydrocortisone plus fludrocortisone than among those who received  placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Min- istry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT",1,12,0.8290078639984131
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf,"- cortisone plus fludrocortisone than with placebo.  Corticosteroids attenuate inflammation in various  organs in both animals and humans with sepsis,  an effect partly related to inhibition of nuclear  factor κB (NF-κB).21 In our trial, hydrocortisone- plus-fludrocortisone therapy accelerated the reso- lution of organ failure in adults with septic shock. Probability of a SOFA",7,99,0.827498197555542
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf," After  the withdrawal of Xigris from the market, the  exclusion criteria that were relevant only to  drotrecogin alfa (activated) were removed.13 (Pro- tocol amendments are detailed in the Supple- mentary Appendix, available at NEJM.org.) Randomization and Trial Agents Patients were randomly assigned in permuted  blocks of eight to receive hydrocortisone-plus- fludrocortisone therapy, drotrecogin al",3,33,0.827498197555542
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf,"in alfa  (activated) given alone or in combination. After  the withdrawal of Xigris from the market in Oc- tober 2011, the trial continued with two parallel  groups. The effects of drotrecogin alfa (activated)  have been reported previously14; in the current  article, we report on the effects of hydrocortisone- plus-fludrocortisone therapy. All the authors had  full and independent access to all",2,26,0.827498197555542
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,APROCCHSS.pdf,"isone or with drotrecogin alfa (activated), which can modulate  the host response, would improve the clinical outcomes of patients with septic shock. METHODS In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we  evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (ac- tivated), the combination of the three",1,4,0.827498197555542
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,ANNANE.pdf,"CARING FOR THE CRITICALLY ILL PATIENT Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock Djillali Annane, MD, PhD Ve´ronique Se´bille, PhD Claire Charpentier, MD Pierre-Edouard Bollaert, MD, PhD Bruno Franc¸ois, MD Jean-Michel Korach, MD Gilles Capellier, MD",1,1,0.8204352855682373
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,CORTICUS.pdf," no response to corticotropin who  received hydrocortisone and fludrocortisone. Our  trial, called the Corticosteroid Therapy of Septic  Shock (CORTICUS) study, evaluated the efficacy  and safety of low-dose hydrocortisone therapy in  a broad population of patients with septic shock  — in particular, patients who had had a response  to a corticotropin test, in whom a benefit was ",2,22,0.817042350769043
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,HYPRESS.pdf," the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use only in patients with inadequate response to fluid and vasopressor resuscitation.2 However, septic shock rever- sal in the CORTICUS study was reported to be significantly ac- celerated by the administration of hydrocortisone irrespec- tive of the adrenal response to corticotropin. An international consensus statement recommended replacing the terms rela- tive",2,19,0.8091700077056885
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,HYPRESS.pdf," 2 randomized clinical trials (RCTs).2 In the study by Annane et al,3 hydro- cortisone improved survival and reversal of septic shock in pa- tients with relative adrenal insufficiency. In the CORTICUS study,4 septic shock was reversed more quickly but mortality was not significantly reduced. The higher risk of mortality and septic shock severity in the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use",2,18,0.8091700077056885
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,PLMALDHSS.pdf,"SS [Activated Protein C and Corticosteroids for Septic Shock4] and ADRENAL [Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock5]) investigated the effects of an intravenous dose of 200 mg hydrocortisone for 7 days and reported conﬂicting effects on mortality; they both reported earlier shock reversal and earlier libera- tion from mechanical ventilation with glucocorticoids, how- ever. Several",2,18,0.808213472366333
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,HYPRESS.pdf," SepNet–Critical Care Trials Group IMPORTANCE Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial. OBJECTIVE To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock. DESIGN, SETTING, AND PARTICIPANTS Double-blind,",1,4,0.8038878440856934
13,Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?,ADRENAL.pdf,"one (Pfizer) at a dose  of 200 mg per day or matching placebo (Rad- pharm Scientific). Blinding regarding the trial  regimen was ensured by the supply of hydrocor- tisone and placebo in identical, masked vials.  The integrity of the trial-group assignment was  confirmed by an independent person who as- sessed a random sample of hydrocortisone and  placebo packs from 10% of the trial population  (Table S3A in",3,33,0.8033764362335205
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,HYPRESS.pdf," the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use only in patients with inadequate response to fluid and vasopressor resuscitation.2 However, septic shock rever- sal in the CORTICUS study was reported to be significantly ac- celerated by the administration of hydrocortisone irrespec- tive of the adrenal response to corticotropin. An international consensus statement recommended replacing the terms rela- tive",2,19,0.8843920230865479
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,HYPRESS.pdf," 2 randomized clinical trials (RCTs).2 In the study by Annane et al,3 hydro- cortisone improved survival and reversal of septic shock in pa- tients with relative adrenal insufficiency. In the CORTICUS study,4 septic shock was reversed more quickly but mortality was not significantly reduced. The higher risk of mortality and septic shock severity in the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use",2,18,0.866447925567627
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,HYPRESS.pdf," SepNet–Critical Care Trials Group IMPORTANCE Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial. OBJECTIVE To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock. DESIGN, SETTING, AND PARTICIPANTS Double-blind,",1,4,0.8298976421356201
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,APROCCHSS.pdf," hydrocortisone plus fludrocortisone. There  was some imbalance between the two groups  in the distribution of pathogens, with slightly  more viral infections in the hydrocortisone-plus- fludrocortisone group than in the placebo group. The mechanisms by which corticosteroids may  favorably affect the outcome of patients with  septic shock have been detailed recently.7 In  brief, corticosteroids improve cardiovascular func- tion by restoring",7,97,0.8241024017333984
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,NEvsVP.pdf,"b receptors in the anterior pituitary, leading to the release of adrenocorticotropin hormone, and corticosteroids have been shown to restore the cytokine-mediated downregu- lation of VP receptors (30). Furthermore, the combination of vasopressin and steroids was shown to result in a lower mortality compared with the combination of norepinephrine plus steroids in a less severe septic shock (3, 31). In a subgroup analysis, we divided the",7,81,0.8236219882965088
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,VASST.pdf," than those of norepinephrine in the  subgroup of patients with more severe (as opposed  to less severe) septic shock. Therefore, we strati- fied patients at the time of randomization accord- ing to the baseline dose of norepinephrine. Methods This trial was conducted between July 2001 and  April 2006 in 27 centers in Canada, Australia, and  the United States and was approved by the re- search ethics boards of all participating institu- tions",2,24,0.8236219882965088
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,SS3vsSS2.pdf," we reanalyzed the results from the ALBIOS study [1] - which in 2014 compared the efficacy of the administration of albumin and crystalloids versus crystalloids alone in patients with septic shock - based on the new definition of septic shock. Our aim was to report differences in the populations classified as Shock-2 or Shock-3, highlighting possible advantages and disadvan- tages of this new definition. Methods This study was a retrospective analysis of data from the ALBIOS",2,19,0.8217287063598633
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,TRISS.pdf," Septic Shock (TRISS)  trial to evaluate the effects on mortality of leuko- reduced blood transfusion at a lower versus a  higher hemoglobin threshold among patients  with septic shock who are in the intensive care  unit (ICU). METHODS TRIAL DESIGN AND OVERSIGHT After the approvals from ethics committees and  data-protection agencies were obtained, patients in  32 general ICUs in Denmark, Sweden, Norway, and  Finland underwent screening and randomization",2,28,0.8217287063598633
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,FRESHS.pdf," this randomized controlled trial, we evaluated the efﬁcacy of dynamic measures (stroke volume change during passive leg raise) to guide resuscitation and improve patient outcome. RESEARCH QUESTION: Will resuscitation that is guided by dynamic assessments of ﬂuid responsiveness in patients with septic shock improve patient outcomes? STUDY DESIGN AND METHODS: We conducted a prospective, multicenter, randomized clinical trial at 13 hospitals in the United States and United Kingdom. Patients presented",1,3,0.8217287063598633
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,ADRENAL.pdf,"rocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation in an inten- sive care unit (ICU). We conducted the trial in  Australia, the United Kingdom, New Zealand,  Saudi Arabia, and Denmark. The trial management committee designed the  trial. The trial sponsor (the George Institute for  Global Health, Australia) coordinated all the  operational processes and conducted all the sta- tistical analyses. Trained research coordinators",2,22,0.8217287063598633
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,APROCCHSS.pdf,"isone or with drotrecogin alfa (activated), which can modulate  the host response, would improve the clinical outcomes of patients with septic shock. METHODS In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we  evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (ac- tivated), the combination of the three",1,4,0.8140547275543213
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,SS3vsSS2.pdf," degli Studi di Milano, Milan, Italy. 9University of Milan-Bicocca, School of Medicine and Surgery, Monza, Italy. Table 3 Enrolment rate of septic shock patients in recent randomized controlled trials on sepsis Study TRISS [5] SEPSISPAM [6] ProCESS [7] ARISE [8] ALBIOS [1] VASST [12] Patients enrolled (n) 1005 776 13",6,83,0.8111732006072998
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,CORTICUS.pdf,"n engl j med 358;2  www.nejm.org  january 10, 2008 111 The new england   journal of medicine established in 1812	 january 10, 2008	 vol. 358  no. 2 Hydrocortisone Therapy for Patients with Septic Shock Charles L. Sprung, M.D., Djillali Annane, M.D., Ph.D., Didier Keh, M.D., Rui",1,1,0.8108968734741211
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,CORTICUS.pdf,"Hydrocortisone therapy for patients with Septic Shock n engl j med 358;2  www.nejm.org  january 10, 2008 113 and members of the monitoring board remained  unaware of study-group assignments throughout  the study period. Study Drugs Hydrocortisone (Rotexmedica) was prepared in  vials containing 100 mg of hydrocortisone hemi­ succinate powder with ampules containing 2 ml  of sterile",3,32,0.8108968734741211
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,PAC-in-FACTT.pdf," the treatment of severe sepsis  and septic shock. N Engl J Med 2001, 345:1368-1377.    18.  Wiener RS, Welch HG: Trends in the use of the  pulmonary artery catheter in the United States,  1993-2004. JAMA 2007, 298:423-429.    19.  Rubenfeld GD, McNamara-Aslin E, Rubinson L: The  pulmonary artery catheter",3,42,0.8108968734741211
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,PLMALDHSS.pdf,"anian Venkatesh, M.D.,11,28 Ruiqiang Zheng, M.D.,29 and Anthony Delaney, M.D., Ph.D.11,30,31 Abstract BACKGROUND Trials and study-level meta-analyses have failed to resolve the role of cor- ticosteroids in the management of patients with septic shock. Patient-level meta-analyses may provide more precise estimates of treatment effects, particularly subgroup effects. METHOD",1,5,0.8108968734741211
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,NSS.pdf,"Volume 22, no. 2: March 2021	 201	 Western Journal of Emergency Medicine Azfar Ruslan et al.	 Norepinephrine in Septic Shock Norepinephrine was superior to other vasopressors in  reducing the incidence of arrhythmia (RR 0.64; 95%  CI, 0.42 to 0.97; P = 0.030; I2 = 64%; six trials, 3,974  participants: moderate quality of evidence)",6,65,0.8108968734741211
14,Does steriods hasten the reversal of shock in patients whom had septic shock reversed?,APROCCHSS.pdf,"-fludrocortisone therapy or drotre- cogin alfa (activated) would improve the clinical  outcomes of patients with septic shock. Methods Trial Design and Oversight Information on the design and conduct of the  Activated Protein C and Corticosteroids for Hu- man Septic Shock (APROCCHSS) trial, including  the trial protocol and amendments and the sta- tistical analysis plan, was published previously13  and is available with the full text",2,23,0.8108968734741211
15,Does early administration of acetaminophen to treat fever affect the number of ICU-free days,HEAT.pdf," patients with an ICU admission diagno- sis of infection.10,11 The lack of high-level evidence12 leaves ICU  clinicians uncertain about whether acetamino- phen treatment of fever due to probable infection  is beneficial, ineffective, or harmful. To address  this uncertainty, we conducted a multicenter,  blinded, randomized, controlled trial to evaluate  the hypothesis that administration of intrave- nous acetaminophen to treat fever would worsen  outcomes. Specifically,",2,15,0.887364387512207
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PROWESS.pdf,"The New England   Journal    of    Medicine   Copyright © 2001 by the Massachusetts Medical Society   VOLUME 344   M   ARCH    8, 2001   NUMBER 10   EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C  FOR SEVERE SEPSIS   G   ORDON    R. B   ERNARD   ,",1,1,0.9144930839538574
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PROWESS-SHOCK.pdf,"The new engl and jour nal of medicine n engl j med 366;22  nejm.org  may 31, 2012 2056 R ecombinant human activated pro- tein C, or drotrecogin alfa (activated)  (DrotAA), was approved for the treatment  of severe sepsis in 2001 on the basis of the Pro- spective Recombinant Human Activated Protein C  Worldwide Evaluation in Severe Sep",2,14,0.9027323722839355
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,SADASS.pdf," safety monitored for 7 days in countries outside the USA. PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; ENHANCE, Extended Evaluation of Recombinant Human Activated Protein C.",2,29,0.9008359909057617
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PROWESS-SHOCK.pdf,"  Care Unit, Bullfinch Bldg., Rm. 148, Massa- chusetts General Hospital, 55 Fruit St.,  Boston, MA 02114, or at tthompson1@ partners.org. Drs. Ranieri and Thompson contributed  equally to this article. *	Investigators in the Prospective Recom- binant Human Activated Protein C World- wide Evaluation in Severe Sepsis and  Septic Shock (PROWESS-SHOCK",1,5,0.8773155212402344
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PROWESS.pdf,"ant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with se- vere sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis. ",1,8,0.8494105339050293
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,LOVIT.pdf," with sepsis  is of low certainty.8,11 In the phase 3, multicenter, randomized,  controlled Lessening Organ Dysfunction with  Vitamin C (LOVIT) trial, we tested the hypoth- esis that a high dose of vitamin C would reduce  the risk of death or persistent organ dysfunc- tion at 28 days in adults with sepsis who were  receiving vasopressor therapy in the intensive  care unit (ICU). Methods Trial Design",2,21,0.8453762531280518
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PROWESS.pdf," er in the drotrecogin alfa activated group than in the placebo group (3.5 percent vs. 2.0 percent, P=0.06).   Conclusions   Treatment with drotrecogin alfa acti- vated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.    Copyright © 2001 Massachusetts Medical Society.   From the Division of Allergy, Pulmonary and Critical Care",1,13,0.8420531749725342
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,EDvsLSMENDS.pdf,"Pandharipande et al. Critical Care 2010, 14:R38 http://ccforum.com/content/14/2/R38 Page 7 of 12 be addressed at the time sedative regimens are initiated for MV. Our findings could be the result of either a beneficial effect of DEX in the setting of sepsis, a deleterious effect of LZ in this setting, or both [27]. Benzodiazepines inhibit macrophage function [31,32",7,85,0.8410606384277344
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,CABS.pdf," that the prevalence of maternal sepsis is higher than previously thought, consistent with the IHME Sepsis estimates that maternal sepsis is among the leading causes of sepsis incidence and sepsis- associated mortality globally [3]. Burden of sepsis in Germany Epidemiological data on the burden of sepsis in Germany was obtained from two major prospective point prevalence stud- iesamongintensivecareunit(ICU)patients and nationwide analyses of hospital dis- charge data",3,36,0.8394687175750732
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,APROCCHSS.pdf,"-fludrocortisone therapy or drotre- cogin alfa (activated) would improve the clinical  outcomes of patients with septic shock. Methods Trial Design and Oversight Information on the design and conduct of the  Activated Protein C and Corticosteroids for Hu- man Septic Shock (APROCCHSS) trial, including  the trial protocol and amendments and the sta- tistical analysis plan, was published previously13  and is available with the full text",2,23,0.8386819362640381
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,SADASS.pdf," the study drug infusion period were associated with severe thrombocytopenia (≤30,000/mm3) and/or meningitis. Serious bleeding and ICH events spontaneously reported from commercial use (n = 3991) occurred in 0.9% and 0.2% of patients, respectively. Conclusion Drotrecogin alfa (activated) significantly reduces mortality in severe sepsis. The efficacy and safety profiles of drotrecogin alfa (",1,8,0.8386576175689697
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,EDvsLSMENDS.pdf," of evidence thus converge to support our hypothesis that sedation with DEX may lead to better outcomes for patients with sepsis than benzodiazepine sedation. We therefore conducted an a priori-planned subgroup analysis among patients from the MENDS trial to determine if sedation with DEX compared with LZ in septic and non-septic patients affected clinical outcomes, including duration and prevalence of acute brain dys- function and 28-day mortality. Materials and methods The MENDS study",2,26,0.8343813419342041
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,PLMALDHSS.pdf,"SS [Activated Protein C and Corticosteroids for Septic Shock4] and ADRENAL [Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock5]) investigated the effects of an intravenous dose of 200 mg hydrocortisone for 7 days and reported conﬂicting effects on mortality; they both reported earlier shock reversal and earlier libera- tion from mechanical ventilation with glucocorticoids, how- ever. Several",2,18,0.8339743614196777
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,SADASS.pdf," risk for bleeding (e.g. some patients with multiple trauma) or patients with severe thrombocytopenia (i.e. platelet count ≤30,000/mm3) were excluded from participation. Clini- cal trials of treatment of severe sepsis with other novel thera- peutics that have antithrombotic properties also excluded a similar patient population. Estimates of serious bleeding com- plications in these latter trials ranged between 6.0% [",7,93,0.8329446315765381
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,ALBIOS.pdf," of the  administration of albumin and crystalloids, as  compared with crystalloids alone, targeting a se- rum albumin level of 30 g per liter or more in a  population of patients with severe sepsis. METHODS STUDY OVERSIGHT AND DESIGN We conducted the Albumin Italian Outcome Sep- sis (ALBIOS) study — an investigator-initiated,  multicenter, open-label, randomized, controlled  trial — in 100 intensive",2,24,0.8286697864532471
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,ULS.pdf,"Hyperlactatemia has historically been associated with adverse outcomes in critically ill patients (1) and still represents the strongest outcome indicator in sepsis. Hyperlactatemia, however, may originate from a variety of causes, such as a deﬁcit in oxygen delivery (tissue hypoxia) or impaired oxygen extraction (2), peripheral shunting (3), stress (4), and increased adrenergic stimulation (5). It is not clear, however, in what proportions",2,18,0.8270528316497803
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,EDIS.pdf," which toll-like receptors (TLRs) exert the most profound inﬂammatory response in sepsis (29). Interestingly, endothelial activation during sepsis, as indicated by high circulating levels of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin, and vWF, is correlated with disease severity and mortality (30–32). Endothelial",3,36,0.824127197265625
16,Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?,Rivers Trial.pdf,"1368   ·   N Engl J Med, Vol. 345, No. 19   ·   November 8, 2001   ·   www.nejm.org   The New England Journal of Medicine   EARLY GOAL-DIRECTED THERAPY IN THE TREATMENT OF SEVERE SEPSIS  AND SEPTIC SHOCK   E   MANUEL    R   IVERS  ",1,1,0.821220874786377
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,SS3vsSS2.pdf," we reanalyzed the results from the ALBIOS study [1] - which in 2014 compared the efficacy of the administration of albumin and crystalloids versus crystalloids alone in patients with septic shock - based on the new definition of septic shock. Our aim was to report differences in the populations classified as Shock-2 or Shock-3, highlighting possible advantages and disadvan- tages of this new definition. Methods This study was a retrospective analysis of data from the ALBIOS",2,19,0.9199750423431396
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,SS3vsSS2.pdf," in 100 intensive care units in Italy comparing the administration of 20% albumin and crystalloids versus crystalloids alone in patients with severe sepsis or septic shock. We analyzed data from 1741 patients from ALBIOS with serum lactate measurement available at baseline. We compared group size, physiological variables and 90-day mortality between patients defined by Shock-2 and Shock-3 and between the albumin and crystalloid treatment groups. Results: We compared the Shock-2 and the Shock-",1,4,0.9084477424621582
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,ALBIOS.pdf," of the  administration of albumin and crystalloids, as  compared with crystalloids alone, targeting a se- rum albumin level of 30 g per liter or more in a  population of patients with severe sepsis. METHODS STUDY OVERSIGHT AND DESIGN We conducted the Albumin Italian Outcome Sep- sis (ALBIOS) study — an investigator-initiated,  multicenter, open-label, randomized, controlled  trial — in 100 intensive",2,24,0.9037742614746094
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,ALBIOS.pdf," DISCUSSION The main results of this large-scale trial provide  evidence regarding both the efficacy and the  safety of the use of human albumin during se- vere sepsis — an interventional strategy that has  long been debated.21,22 The addition of albumin  to crystalloids during the first 28 days of treat- ment to maintain a serum albumin level of 30 g  per liter or more is safe but does not provide a  survival advantage over crystalloids",6,85,0.8668539524078369
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,ULS.pdf," (ScvO2) and that the presence or absence of kidney injury determines the ﬁnal effect of plasma lactate concentration on pH. Methods Patients This study is a secondary analysis of the ALBIOS study (8), a multicenter randomized controlled trial conducted between 2008 and 2012 in 100 Italian ICUs that compared the effects of 20% albumin and crystalloids versus crystalloids alone in severe sepsis and septic shock. In the present study, we included 1,7",2,23,0.8339035511016846
17,Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival,SS3vsSS2.pdf," Shock-3, Sepsis, Albumin, Crystalloids, ALBIOS * Correspondence: gattinoniluciano@gmail.com 1Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Straße, 40, 37075 Göttingen, Germany Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the",1,9,0.8055596351623535
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,SAFE.pdf,":2247-56.   Copyright © 2004 Massachusetts Medical Society.   background    It remains uncertain whether the choice of resuscitation fluid for patients in intensive care units (ICUs) affects survival. We conducted a multicenter, randomized, double-blind trial to compare the effect of fluid resuscitation with albumin or saline on mortality in a heterogeneous population of patients in the ICU.   methods    We randomly assigned patients who had been admitted to the IC",1,5,0.917517900466919
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,SAFE.pdf,"n engl j med    350;22   www.nejm.org may    27, 2004   The    new england journal    of    medicine   2247   original article   A Comparison of Albumin and Saline for Fluid  Resuscitation in the Intensive Care Unit   The SAFE Study Investigators*   The Saline versus Albumin Fluid Evalua- tion (SA",1,1,0.8934433460235596
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,SAFE.pdf," death in a general population of patients and did not find a significant increase in the risk of death.   3   The conflicting results of such meta-analyses have left many clinicians unsure about the effect of albumin-containing fluids on survival in critically ill patients. To address this uncertainty, we conducted the Saline versus Albumin Fluid Evaluation (SAFE) Study in 16 ICUs in Australia and New Zealand. We tested the hypothesis that when 4 percent albumin is compared with 0",2,16,0.870661735534668
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,FEAST.pdf," sub-Saha- ran Africa receive no specific fluid management  apart from blood transfusion for severe anemia17  or maintenance fluids. The Fluid Expansion as Supportive Therapy  (FEAST) study was designed to investigate the  practice of early resuscitation with a saline bolus  as compared with no bolus (control) and with an  albumin bolus as compared with a saline bolus. Methods Design and Treatment Protocol We conducted this two-stratum, multicenter,",2,26,0.8352251052856445
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,SADASS.pdf,"in alfa (activated) in commercial use was estimated from the total number of courses of therapy sold in the USA using hospital- based stores information from 21 November 2001 until 12 April 2002. Drug administration Table 1 lists details of drug dose and durations of infusion for each clinical trial. Patients randomly assigned to placebo in the controlled clinical trials received either saline or 0.1% albumin in saline. Based on the approved recommendations for the USA [6], patients receiving drotrecogin alfa",3,31,0.8203592300415039
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,DDS.pdf," issue of Critical Care, Hernandez et al. [15] tested both esmolol and dexmedetomidine in a sheep model of endotoxic shock with systemic hypotension, pulmonary hypertension, and hyperlactataemia. After a brief phase of fluid resuscitation and haemodynamic stabilisation with norepinephrine, animals were rando- mised to receive dexmedetomidine, esmolol, or pla- cebo. Despite the early use of sympatholy",1,8,0.8143875598907471
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,SS3vsSS2.pdf," The Sepsis-3 definition reduced the size of the population with shock and showed a similar effect size in the benefits of albumin. The Shock-3 criteria will markedly slow patients’ recruitment rates, in view of testing albumin in septic shock. Trial registration: ClinicalTrials.gov, number NCT00707122. Registered on 30 June 2008. Keywords: Septic shock, Shock-3, Sepsis, Albumin, Crystalloids, ALBIOS * Correspondence",1,8,0.8049454689025879
18,Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?,ALBIOS.pdf,"original article The new engl and jour nal of medicine n engl j med 370;15  nejm.org  april 10, 2014 1412 Albumin Replacement in Patients   with Severe Sepsis or Septic Shock Pietro Caironi, M.D., Gianni Tognoni, M.D., Serge Masson, Ph.D.,   Roberto Fumagalli, M.D., Antonio Pesenti, M.D",1,1,0.8038747310638428
19,Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?,Rivers Trial.pdf,"  22   The patients assigned to early goal-directed therapy received a central venous catheter capable of measuring central venous oxygen saturation (Edwards Lifesciences, Irvine, Calif.); it was connected to a computerized spectrophotometer for continuous monitoring. Patients were treated in the emergency department according to a protocol for early goal-directed therapy (Fig. 2) for at least six hours and were transferred to the first available inpatient beds. Monitoring of central venous oxygen",3,39,0.8235747814178467
19,Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?,Rivers Trial.pdf,"1368   ·   N Engl J Med, Vol. 345, No. 19   ·   November 8, 2001   ·   www.nejm.org   The New England Journal of Medicine   EARLY GOAL-DIRECTED THERAPY IN THE TREATMENT OF SEVERE SEPSIS  AND SEPTIC SHOCK   E   MANUEL    R   IVERS  ",1,1,0.8235747814178467
19,Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?,ARISE.pdf," sepsis.7 Reported in-hospital mortality  ranges in this subgroup from 20 to 50%.3,8-10 In  2001, a proof-of-concept, randomized trial showed  that early hemodynamic resuscitation according  to a specific protocol termed early goal-directed  therapy (EGDT) improved outcomes in patients  presenting to the emergency department with  severe sepsis, as compared with usual therapy.11 EGDT was subsequently incorporated into the  6-hour resusc",2,15,0.812368631362915
19,Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?,ProCESS.pdf," the short-term mor- tality is 20% or more.2,3 In 2001, Rivers et al. re- ported that among patients with severe sepsis or  septic shock in a single urban emergency depart- ment, mortality was significantly lower among  those who were treated according to a 6-hour  protocol of early goal-directed therapy (EGDT)  than among those who were given standard ther- apy (30.5% vs. 46.5%).",2,16,0.8016140460968018
19,Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?,ProCESS.pdf," to the emergency department with severe sepsis and septic shock, mortality  was markedly lower among those who were treated according to a 6-hour protocol  of early goal-directed therapy (EGDT), in which intravenous fluids, vasopressors,  inotropes, and blood transfusions were adjusted to reach central hemodynamic  targets, than among those receiving usual care. We conducted a trial to determine  whether these findings were generalizable and whether all aspects of the protocol ",1,7,0.8016140460968018
20,Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?,PROWESS-SHOCK.pdf," DrotAA received marketing authorization from  the European Medicines Agency for the treatment  of adults with severe sepsis and multiple organ  failure, but the approval was subject to annual  review.7 In 2007, the agency concluded that suf- ficient doubt existed to warrant a new placebo- controlled trial.8 We conducted the PROWESS- SHOCK study to test the hypothesis that DrotAA,  as compared with placebo, would reduce mortal- ity in patients with se",2,19,0.8941962718963623
20,Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?,PROWESS-SHOCK.pdf,"n engl j med 366;22  nejm.org  may 31, 2012 2055 The new england  journal of medicine established in 1812	 may 31, 2012	 vol. 366  no. 22 Drotrecogin Alfa (Activated) in Adults with Septic Shock V. Marco Ranieri, M.D., B. Taylor Thompson, M.D., Philip S. Barie, M.D., M.B.A",1,1,0.8480000495910645
20,Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?,SADASS.pdf,"Available online http://ccforum.com/content/7/2/155 Research Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis Gordon R Bernard1, William L Macias2, David E Joyce3, Mark D Williams3, Joan Bailey4 and Jean-Louis Vincent5 1Director, Division of Allergy, Pulmonary and Critical Care, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 2Medical Director,",1,1,0.8266162872314453
20,Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?,APROCCHSS.pdf,"isone or with drotrecogin alfa (activated), which can modulate  the host response, would improve the clinical outcomes of patients with septic shock. METHODS In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we  evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (ac- tivated), the combination of the three",1,4,0.8006155490875244
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",TTM2.pdf,"- ber, NCT02908308.) ABSTR ACT Hypothermia versus Normothermia   after Out-of-Hospital Cardiac Arrest J. Dankiewicz, T. Cronberg, G. Lilja, J.C. Jakobsen, H. Levin, S. Ullén, C. Rylander,  M.P. Wise, M. Oddo, A. Cariou, J. Bělohlávek, J.",1,10,0.9155704975128174
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",THvsTN.pdf,"atose cardiac arrest survivors, similar to a phase-III drug trial. To address this evidence gap we have designed the TTM2-trial, to compare hypothermia with a control group targeting normothermia with early treatment of fever. To ensure that the TTM2 trial is warranted, on 26th September 2018 we searched for trials assessing the effects of hypothermia after out-of-hospital cardiac arrest in PubMed. We found no new randomized trials comparing hypothermia with normother",2,24,0.906022310256958
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HACA-LA.pdf,"20. Bernard SA, Jones BM. Treatment of comatose survivors of out-of- hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;7. 21. Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118–21. https:// doi.",7,100,0.9019982814788818
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",TCAIHCA.pdf,"*; Stefan Kluge, MD*;   for the Hypothermia After In-Hospital Cardiac Arrest Study Group BACKGROUND: This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac  arrest (IHCA) on mortality and functional outcome as compared with normothermia. METHODS: An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing  hypothermic temperature control",1,6,0.899972677230835
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HACA-LA.pdf,"rev.2004.12.028. 18. Leonov Y, Sterz F, Safar P, et al. Mild cerebral hypothermia during and after cardiac arrest improves neurologic outcome in dogs. J Cereb Blood Flow Metab 1990;10:57–70. https://doi.org/10.1038/ jcbfm.1990.8. 19. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic",6,98,0.8995192050933838
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HACA.pdf," centers for their enthusiastic cooperation, to Elaine Ward for editorial as- sistance, and to the patients in the study for their trust and support.  APPENDIX The following investigators participated in the Hypothermia after Cardi- ac Arrest Study Group (the number of patients enrolled at each center is shown): Chair, Central Coordinating Office —M. Holzer (Univer- sitätsklinik für Notfallmedizin, Vienna, Austria); Steering Committee — E",7,95,0.8980910778045654
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",RIC.pdf,".** 42. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-556.** 43. Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascu- lar Care. Circulation. 2015;132:",5,78,0.8980910778045654
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",THvsTN.pdf,"Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial—Rationale and design Josef Dankiewicz, a Tobias Cronberg, b Gisela Lilja, b Janus Christian Jakobsen, c Jan Bělohlávek, d Clifton Callaway, e Alain Cariou, f Glenn Eastwood, g David Erlinge, a Jan Hovden",1,1,0.8975348472595215
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",TCAIHCA.pdf,"HCA this randomized con- trolled multicenter trial was initiated. METHODS Study Design The HACA in-hospital trial (Hypothermia After Cardiac Arrest  in-hospital) was an investigator-initiated, multicenter, open- label, blinded outcome–assessed, randomized, controlled  trial recruiting patients from 13 intensive care units in 11  participating hospitals (4 university hospitals and 7 com- munity hospitals). The study protocol was approved by the  local ethics committees",2,20,0.8947985172271729
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",CETHACA.pdf," (HACA) study group reported that therapeutic hypothermia improves survival and neurological outcomes in comatose resuscitated patients after OHCA.4,5 A subsequent meta-analysis demonstrated that an average of 6 (95% confidence interval 4 to 13) patients with OHCA needed to be treated with hypothermia for 1 additional patient to be discharged with good neurological outcome.6 In 2005 the American Heart Association recommended that comatose cardiac arrest survivors receive induced hypother- mia after ventricular",1,8,0.8945424556732178
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HNPCASR.pdf,Taccone et al. Critical Care          (2024) 28:335   https://doi.org/10.1186/s13054-024-05119-3 RESEARCH Hypothermia versus normothermia  in patients with cardiac arrest and shockable  rhythm: a secondary analysis of the TTM‑2 study Fabio Silvio Taccone,1,1,0.8847980499267578
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HNPCASR.pdf,"5  °C remains  unclear [12]. On the opposite, the European Society for  Emergency Medicine (EUSEM) and the European Society  of Anesthesiology and Intensive Care (ESAIC) advocated  for the consideration of hypothermia within the range of  32–34 °C for a duration of 24 h in all adult patients fol- lowing cardiac arrest, as promptly as possible [13], using  findings from another meta-analysis [14]. Our",5,61,0.882728099822998
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",CETHACA.pdf,"imi-Idrissi S, Roine RO, Sterz F, Mullner M. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med. 2005;33: 414–418. 7. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005; 112:IV1–203. 8. Merchant RM, Soar J, Skrifvars MB",7,95,0.8763105869293213
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",CETHACA.pdf," Stein- berger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statis- tics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25–e146. 4. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–556. 5. Bernard SA, Gray TW, Buist MD, Jones",7,93,0.8741211891174316
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",HNPCASR.pdf," Hypothermia after Cardiac Arrest (HACA)  trial [4], only patients with witnessed OHCA, an initial  shockable rhythm and other specific inclusion criteria  were randomized; those who received hypothermia at  33  °C had better neurological outcome than controls.  Moreover, in another small trial including patients with  similar characteristics [5], hypothermia initiated using  pre-hospital cooling was associated with improved func- tional outcome and survival when compared to normo-",2,21,0.8736579418182373
21,"In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?",MPOHCAUSPITHRCA.pdf,rst 24 h following reperfusion critically deter- mine the extent of brain damage (1). Therapeutic hypothermia with a target tem- perature of 32C to 34C had been established as a standard procedure for treatment of patients with OHCA to reduce consumption of and demand for oxygen by the brain. In the randomized controlled Hypothermia After Cardiac Arrest (HACA) trial lowering body core temperature to 33C for 24 h reduced mortality and improved neurological outcome,2,14,0.8736579418182373
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TTM.pdf,"The new engl and jour nal of medicine n engl j med 369;23  nejm.org  december 5, 2013 2197 original article Targeted Temperature Management   at 33°C versus 36°C after Cardiac Arrest Niklas Nielsen, M.D., Ph.D., Jørn Wetterslev, M.D., Ph.D., Tobias Cronberg, M.D., Ph.D.,  David Erlinge, M",1,1,0.9255146980285645
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HACA-LA.pdf," In 2013, and in 2021, two large randomized trials showed no beneﬁt of targeting a temperature of 33 C compared to either 36 C or avoiding fever (<37.8 C) post-cardiac arrest.23,24 The neuroprotective effect of post-ischemic hypothermia in clinical practice was thus questioned. A recent systematic review and meta-analysis has shown no beneﬁt and current international guidelines do not recommend its use",2,16,0.9206259250640869
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",THvsTN.pdf,". It is registered at clinicaltrial.gov (NCT02908308). The full trial protocol is available at www.ttm2trial.org. The TTM2-trial is an international, multicenter, parallel group, investigator-initiated, randomized, supe- riority trial in which a target temperature of 33°C after cardiac arrest will be compared with a target of normothermia with early treatment of fever (≥37.8°C). As",2,27,0.9116015434265137
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TCAIHCA.pdf,"*; Stefan Kluge, MD*;   for the Hypothermia After In-Hospital Cardiac Arrest Study Group BACKGROUND: This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac  arrest (IHCA) on mortality and functional outcome as compared with normothermia. METHODS: An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing  hypothermic temperature control",1,6,0.905724287033081
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TTM.pdf," benefits and harms of two  targeted temperature regimens, both intended to  prevent fever, in a broader population of patients  with cardiac arrest than previously studied. Methods Trial Design The Target Temperature Management 33°C versus  36°C after Out-of-Hospital Cardiac Arrest (TTM)  trial was a randomized clinical trial recruiting  patients in 36 intensive care units (ICUs) in Eu- rope and Australia. The rationale for and design  of the trial, as well",2,21,0.9055838584899902
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HNPCASR.pdf,"5  °C remains  unclear [12]. On the opposite, the European Society for  Emergency Medicine (EUSEM) and the European Society  of Anesthesiology and Intensive Care (ESAIC) advocated  for the consideration of hypothermia within the range of  32–34 °C for a duration of 24 h in all adult patients fol- lowing cardiac arrest, as promptly as possible [13], using  findings from another meta-analysis [14]. Our",5,61,0.9042036533355713
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",RIC.pdf,". Bro-Jeppesen J, Kjaergaard J, Wanscher M, et al. The inflamma- tory response after out-of-hospital cardiac arrest is not modified by targeted temperature management at 33C or 36C. Resuscita- tion. 2014;85(11):1480-1487.** 46. Bro-Jeppesen J, Kjaergaard J, Stammet P, et al; TTM-",5,80,0.8903472423553467
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TCAIHCA.pdf,".060106. For Sources of Funding and Disclosures, see page 1365. © 2022 American Heart Association, Inc.  ORIGINAL RESEARCH ARTICLE Temperature Control After In-Hospital Cardiac  Arrest: A Randomized Clinical Trial Sebastian Wolfrum, MD*; Kevin Roedl , MD*; Alexia Hanebutte, MD; Rüdiger Pfeifer, MD; Volkhard Kurowski, MD;   Reimer Riessen",1,4,0.87544846534729
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TCAIHCA.pdf,"ORIGINAL RESEARCH  ARTICLE November 1, 2022 Circulation. 2022;146:1357–1366. DOI: 10.1161/CIRCULATIONAHA.122.060106 1358 Wolfrum et al Temperature Control After In-Hospital Cardiac Arrest A dults who are unconscious after cardiac arrest  should be treated with temperature control to  actively prevent fever in accordance with the  2022 recommendations from the International Liaison  Committee on Resuscitation",2,15,0.8726997375488281
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",THvsTN.pdf,"atose cardiac arrest survivors, similar to a phase-III drug trial. To address this evidence gap we have designed the TTM2-trial, to compare hypothermia with a control group targeting normothermia with early treatment of fever. To ensure that the TTM2 trial is warranted, on 26th September 2018 we searched for trials assessing the effects of hypothermia after out-of-hospital cardiac arrest in PubMed. We found no new randomized trials comparing hypothermia with normother",2,24,0.8697924613952637
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HACA-LA.pdf,"rev.2004.12.028. 18. Leonov Y, Sterz F, Safar P, et al. Mild cerebral hypothermia during and after cardiac arrest improves neurologic outcome in dogs. J Cereb Blood Flow Metab 1990;10:57–70. https://doi.org/10.1038/ jcbfm.1990.8. 19. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic",6,98,0.8697919845581055
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HACA.pdf," centers for their enthusiastic cooperation, to Elaine Ward for editorial as- sistance, and to the patients in the study for their trust and support.  APPENDIX The following investigators participated in the Hypothermia after Cardi- ac Arrest Study Group (the number of patients enrolled at each center is shown): Chair, Central Coordinating Office —M. Holzer (Univer- sitätsklinik für Notfallmedizin, Vienna, Austria); Steering Committee — E",7,95,0.8671014308929443
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",RIC.pdf,".** 42. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-556.** 43. Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascu- lar Care. Circulation. 2015;132:",5,78,0.8671014308929443
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HNPCASR.pdf,"  the TTM-2 trial to evaluate whether therapeutic hypo- thermia at 33  °C was linked to decreased likelihood  of mortality and/or of adverse functional outcome in  patients with similar baseline characteristics to those in  the HACA trial. Methods Study design We conducted a post hoc secondary analysis of the  TTM-2 trial (NCT02908308), which was an interna- tional, multicenter randomized controlled trial compar- ing the effects of hypothermia",2,25,0.8644070625305176
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TTM2.pdf,"- ber, NCT02908308.) ABSTR ACT Hypothermia versus Normothermia   after Out-of-Hospital Cardiac Arrest J. Dankiewicz, T. Cronberg, G. Lilja, J.C. Jakobsen, H. Levin, S. Ullén, C. Rylander,  M.P. Wise, M. Oddo, A. Cariou, J. Bělohlávek, J.",1,10,0.8626284599304199
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",TCAIHCA.pdf,"HCA this randomized con- trolled multicenter trial was initiated. METHODS Study Design The HACA in-hospital trial (Hypothermia After Cardiac Arrest  in-hospital) was an investigator-initiated, multicenter, open- label, blinded outcome–assessed, randomized, controlled  trial recruiting patients from 13 intensive care units in 11  participating hospitals (4 university hospitals and 7 com- munity hospitals). The study protocol was approved by the  local ethics committees",2,20,0.8611235618591309
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",THvsTN.pdf,"Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial—Rationale and design Josef Dankiewicz, a Tobias Cronberg, b Gisela Lilja, b Janus Christian Jakobsen, c Jan Bělohlávek, d Clifton Callaway, e Alain Cariou, f Glenn Eastwood, g David Erlinge, a Jan Hovden",1,1,0.857107400894165
22,"In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33°C provide any benefit compared with a targeted temperature of 36°C?",HACA-LA.pdf,"20. Bernard SA, Jones BM. Treatment of comatose survivors of out-of- hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;7. 21. Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118–21. https:// doi.",7,100,0.8560736179351807
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",RIC.pdf,".** 42. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-556.** 43. Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascu- lar Care. Circulation. 2015;132:",5,78,0.9224300384521484
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",CETHACA.pdf," Stein- berger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statis- tics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25–e146. 4. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–556. 5. Bernard SA, Gray TW, Buist MD, Jones",7,93,0.9224300384521484
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HACA-LA.pdf,"20. Bernard SA, Jones BM. Treatment of comatose survivors of out-of- hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;7. 21. Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118–21. https:// doi.",7,100,0.9071207046508789
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",THvsTN.pdf,"atose cardiac arrest survivors, similar to a phase-III drug trial. To address this evidence gap we have designed the TTM2-trial, to compare hypothermia with a control group targeting normothermia with early treatment of fever. To ensure that the TTM2 trial is warranted, on 26th September 2018 we searched for trials assessing the effects of hypothermia after out-of-hospital cardiac arrest in PubMed. We found no new randomized trials comparing hypothermia with normother",2,24,0.8852846622467041
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HACA-LA.pdf,"rev.2004.12.028. 18. Leonov Y, Sterz F, Safar P, et al. Mild cerebral hypothermia during and after cardiac arrest improves neurologic outcome in dogs. J Cereb Blood Flow Metab 1990;10:57–70. https://doi.org/10.1038/ jcbfm.1990.8. 19. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic",6,98,0.8841774463653564
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HACA.pdf," centers for their enthusiastic cooperation, to Elaine Ward for editorial as- sistance, and to the patients in the study for their trust and support.  APPENDIX The following investigators participated in the Hypothermia after Cardi- ac Arrest Study Group (the number of patients enrolled at each center is shown): Chair, Central Coordinating Office —M. Holzer (Univer- sitätsklinik für Notfallmedizin, Vienna, Austria); Steering Committee — E",7,95,0.8833715915679932
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",CETHACA.pdf,"imi-Idrissi S, Roine RO, Sterz F, Mullner M. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med. 2005;33: 414–418. 7. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005; 112:IV1–203. 8. Merchant RM, Soar J, Skrifvars MB",7,95,0.8797905445098877
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",TTM2.pdf,"- ber, NCT02908308.) ABSTR ACT Hypothermia versus Normothermia   after Out-of-Hospital Cardiac Arrest J. Dankiewicz, T. Cronberg, G. Lilja, J.C. Jakobsen, H. Levin, S. Ullén, C. Rylander,  M.P. Wise, M. Oddo, A. Cariou, J. Bělohlávek, J.",1,10,0.8788583278656006
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",TCAIHCA.pdf,"*; Stefan Kluge, MD*;   for the Hypothermia After In-Hospital Cardiac Arrest Study Group BACKGROUND: This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac  arrest (IHCA) on mortality and functional outcome as compared with normothermia. METHODS: An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing  hypothermic temperature control",1,6,0.8778936862945557
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",RIC.pdf," TE, van der Hoeven JG. Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit Care Med. 2012;40(4): 1136-1142.** 54. Bisschops LL, van der Hoeven JG, Mollnes TE, Hoedemaekers CW. Seventy-two hours of mild hypothermia after cardiac arrest is associated with a lowered inflammatory response during rewarming in a prospective observational study. Crit Care",5,86,0.8774712085723877
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",CETHACA.pdf," (HACA) study group reported that therapeutic hypothermia improves survival and neurological outcomes in comatose resuscitated patients after OHCA.4,5 A subsequent meta-analysis demonstrated that an average of 6 (95% confidence interval 4 to 13) patients with OHCA needed to be treated with hypothermia for 1 additional patient to be discharged with good neurological outcome.6 In 2005 the American Heart Association recommended that comatose cardiac arrest survivors receive induced hypother- mia after ventricular",1,8,0.8750393390655518
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",TCAIHCA.pdf,"HCA this randomized con- trolled multicenter trial was initiated. METHODS Study Design The HACA in-hospital trial (Hypothermia After Cardiac Arrest  in-hospital) was an investigator-initiated, multicenter, open- label, blinded outcome–assessed, randomized, controlled  trial recruiting patients from 13 intensive care units in 11  participating hospitals (4 university hospitals and 7 com- munity hospitals). The study protocol was approved by the  local ethics committees",2,20,0.8745057582855225
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HNPCASR.pdf,Taccone et al. Critical Care          (2024) 28:335   https://doi.org/10.1186/s13054-024-05119-3 RESEARCH Hypothermia versus normothermia  in patients with cardiac arrest and shockable  rhythm: a secondary analysis of the TTM‑2 study Fabio Silvio Taccone,1,1,0.8691515922546387
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HNPCASR.pdf,"5  °C remains  unclear [12]. On the opposite, the European Society for  Emergency Medicine (EUSEM) and the European Society  of Anesthesiology and Intensive Care (ESAIC) advocated  for the consideration of hypothermia within the range of  32–34 °C for a duration of 24 h in all adult patients fol- lowing cardiac arrest, as promptly as possible [13], using  findings from another meta-analysis [14]. Our",5,61,0.8663043975830078
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HNPCASR.pdf," Hypothermia after Cardiac Arrest (HACA)  trial [4], only patients with witnessed OHCA, an initial  shockable rhythm and other specific inclusion criteria  were randomized; those who received hypothermia at  33  °C had better neurological outcome than controls.  Moreover, in another small trial including patients with  similar characteristics [5], hypothermia initiated using  pre-hospital cooling was associated with improved func- tional outcome and survival when compared to normo-",2,21,0.863971471786499
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",MPOHCAUSPITHRCA.pdf,rst 24 h following reperfusion critically deter- mine the extent of brain damage (1). Therapeutic hypothermia with a target tem- perature of 32C to 34C had been established as a standard procedure for treatment of patients with OHCA to reduce consumption of and demand for oxygen by the brain. In the randomized controlled Hypothermia After Cardiac Arrest (HACA) trial lowering body core temperature to 33C for 24 h reduced mortality and improved neurological outcome,2,14,0.863971471786499
23,"Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?",HACA-LA.pdf,"Experimental paper Hypothermia After Cardiac Arrest in Large Animals (HACA-LA): Study protocol of a randomized controlled experimental trial Olof Persson a,b,*, Anna Valerianova c,d, Jan Beˇlohla´vek e, Tobias Cronberg f,g, Niklas Nielsen a, Elisabet Englund h,i, Mikula´sˇ Mlcˇek d, Hans Friberg a,j Abstract Background:",1,1,0.8637826442718506
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RAEATICU.pdf,"23. [19] Pisani MA, Araujo KLB, Murphy TE. Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. Crit Care Med 2015;43: 996–1002. [20] Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of de- lirium. Psychomantics 2002;43(3):171–2. [21] Sk",5,96,0.9295516014099121
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RAEATICU.pdf," Pharm Pract 2015 (pii: 0897190014566313). [18] Page VJ, Ely EW, Gates S, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomized, double- blind, placebo-controlled trial. Lancet Respir Med 2013;1:515–23. [19] Pisani MA, Araujo KLB, Murphy TE. Association of",5,95,0.9122865200042725
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf,"3829​-­15.) ABSTR ACT Haloperidol for the Treatment of Delirium  in ICU Patients N.C. Andersen‑Ranberg, L.M. Poulsen, A. Perner, J. Wetterslev, S. Estrup,  J. Hästbacka, M. Morgan, G. Citerio, J. Caballero, T. Lange, M.-B.N. Kjær,",1,10,0.9093189239501953
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf," the other studies by Devlin, Skrobik, and Han, the MIND trial demon- strated that neither haloperidol nor ziprasidone was effective for the prevention and treatment of delirium in ICU patients. Therefore, the investigators suggested that a large trial is needed to further determine the role of antipsychotics in the manage- ment of ICU delirium. Pharmacogenetic Implications A substantial amount of interindividual variation in antipsy- chotic response",6,93,0.8805716037750244
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf," evidence demonstrating that haloper- idol reduces the incidence or duration of delirium in ICU patients, the use of haloperidol as a first-line pharmacologic agent for ICU delirium was supported by the previous practice guidelines, published in 2002.5 However, the Pain, Agitation, and Delirium (PAD) guidelines, recently released by the Amer- ican College of Critical Care Medicine and the Society of Crit- ical Care Medicine, downgraded their",1,6,0.8660759925842285
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf," literature varies from 11% to 80%.1,2 Previous studies suggest that delirium is associated with higher mortality rates, longer hospital stay, long-term cognitive impairment, and increased health care cost.3,4 Haloperidol, a first-generation antipsychotic (FGA), has been commonly used for the treatment of ICU delir- ium. Although there is no evidence demonstrating that haloper- idol reduces the incidence or duration of delirium in ICU patients",1,5,0.864734411239624
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RAEATICU.pdf,"irium. Psychomantics 2002;43(3):171–2. [21] Skrobik YK, Bergeron N, Dumont M, et al. Olanzapine vs haloperidol: treating delir- ium in a critical care setting. Intensive Car Med 2004:444–9. [22] Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized",5,97,0.8582026958465576
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf, of early physical and occupational therapy (PT/OT) on functional outcomes in mechanically ventilated patients in the ICU.28 This study demonstrated that the early administra- tion of PT and OT improved functional outcomes and reduced the incidence and duration of ICU delirium. The 2013 updated PAD guidelines strongly support early mobilization whenever feasible for the prevention of delirium.6 Diagnosis An accurate and timely diagnosis of delirium in ICU patients is key to effectively treating delirium;,3,35,0.856987476348877
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,DIICU.pdf," Screening Checklist (ICDSC) [8] and the Confusion Assessment Method for the ICU (CAM-ICU) [50,51] allow nonpsychiatric physicians and other ICU personnel to diagnose delirium in ICU patients rapidly and reliably, even when the patient cannot speak because of endotracheal intubation. In fact, the SCCM [42] recommends that all ICU patients be routinely evaluated for delirium. Bergeron and",5,60,0.8529348373413086
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AMTD.pdf," prac- tice guideline by American College of Critical Care Medicine shows lack of evidence of antipsychotic use for the treatment of delirium in ICU patients,12 no comprehensive data or clinical practice guide- lines have been reported regarding antipsychotic use for the treatment of delirium in non-ICU set- tings. Furthermore, in two randomised controlled trials (RCTs) comparing antipsychotics and placebo in ICU patients with delirium,13 14 most",1,16,0.8505303859710693
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf,"n engl j med 387;26  nejm.org  december 29, 2022 2427 Haloperidol for Delirium in ICU Patients vestigators and clinicians at the trial sites to  screen all the patients fulfilling the inclusion  criteria for enrollment in the trial. Patients could  be assessed for eligibility throughout the entire  ICU stay. Randomization and Blinding Eligible patients were randomly assigned in a 1:1  ratio to receive haloperidol",3,31,0.849846601486206
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf,iri­ um in ICU patients identified only one placebo- controlled trial and concluded that the evidence  for the use of haloperidol to treat delirium in ICU  patients was sparse and inconclusive. We con­ ducted the Agents Intervening against Delirium in  the Intensive Care Unit (AID-ICU) trial to investi­ gate whether treatment with haloperidol would  lead to a greater number of days alive and out of  the,2,19,0.8483970165252686
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf," 50% of pa­ tients being treated in the intensive care unit (ICU)  and is associated with increased morbidity and  mortality.3-7 Haloperidol, a typical antipsychotic compound,  continues to be the most frequently used agent to  treat delirium in ICU patients. Results of an in­ ternational inception-cohort study that were pub­ lished in 2018 showed that approximately half the  ICU patients with delirium received",2,17,0.8483970165252686
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf," in patients receiving haloperidol as opposed to the olanzapine group (6 patients vs 0 patient). This study con- cluded that olanzapine is a safe alternative to haloperidol in ICU patients with delirium. However, this study design was limited by its small sample size, uneven distribution of study drugs between 2 treatment groups due to the odd/even day ran- domization, lack of blinding, and no placebo group. Queti",5,67,0.8452143669128418
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf," with haloperidol would  lead to a greater number of days alive and out of  the hospital than placebo; other clinically im­ portant outcomes in ICU patients with delirium  were also evaluated. Methods Trial Design and Oversight This was a multicenter, blinded, parallel-group,  placebo-controlled clinical trial with centralized  randomization. Patient screening was performed  between June 14, 2018, and April 9, 2022, at 18  general ICUs in Denmark, Finland",2,20,0.8452143669128418
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,RUSGATICUD.pdf,", patients in the quetiapine group experienced more somnolence than those treated with placebo (22% vs 11%, P ¼ .66). This study suggested that treatment with quickly escalating doses of quetiapine may reduce the duration of delir- ium and agitation in ICU patients with delirium. The limita- tions of this study included a small sample size, low external validity due to its restrictive inclusion/exclusion criteria, and the use",6,84,0.8452143669128418
24,Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?,AID-ICU.pdf, pub­ lished in 2018 showed that approximately half the  ICU patients with delirium received haloperidol.8  The use of haloperidol is not supported by clini­ cal practice guidelines because evidence of its  effect is limited.1 A recent systematic review9 of  trials comparing haloperidol with other pharma­ cologic interventions for the treatment of deliri­ um in ICU patients identified only one placebo- controlled trial and concluded that the evidence ,2,18,0.8452143669128418
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf," the other studies by Devlin, Skrobik, and Han, the MIND trial demon- strated that neither haloperidol nor ziprasidone was effective for the prevention and treatment of delirium in ICU patients. Therefore, the investigators suggested that a large trial is needed to further determine the role of antipsychotics in the manage- ment of ICU delirium. Pharmacogenetic Implications A substantial amount of interindividual variation in antipsy- chotic response",6,93,0.8742396831512451
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AMTD.pdf," prac- tice guideline by American College of Critical Care Medicine shows lack of evidence of antipsychotic use for the treatment of delirium in ICU patients,12 no comprehensive data or clinical practice guide- lines have been reported regarding antipsychotic use for the treatment of delirium in non-ICU set- tings. Furthermore, in two randomised controlled trials (RCTs) comparing antipsychotics and placebo in ICU patients with delirium,13 14 most",1,16,0.8256726264953613
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",DIICU.pdf," Screening Checklist (ICDSC) [8] and the Confusion Assessment Method for the ICU (CAM-ICU) [50,51] allow nonpsychiatric physicians and other ICU personnel to diagnose delirium in ICU patients rapidly and reliably, even when the patient cannot speak because of endotracheal intubation. In fact, the SCCM [42] recommends that all ICU patients be routinely evaluated for delirium. Bergeron and",5,60,0.8233249187469482
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf," literature varies from 11% to 80%.1,2 Previous studies suggest that delirium is associated with higher mortality rates, longer hospital stay, long-term cognitive impairment, and increased health care cost.3,4 Haloperidol, a first-generation antipsychotic (FGA), has been commonly used for the treatment of ICU delir- ium. Although there is no evidence demonstrating that haloper- idol reduces the incidence or duration of delirium in ICU patients",1,5,0.8185689449310303
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf,"3829​-­15.) ABSTR ACT Haloperidol for the Treatment of Delirium  in ICU Patients N.C. Andersen‑Ranberg, L.M. Poulsen, A. Perner, J. Wetterslev, S. Estrup,  J. Hästbacka, M. Morgan, G. Citerio, J. Caballero, T. Lange, M.-B.N. Kjær,",1,10,0.8142204284667969
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf,iri­ um in ICU patients identified only one placebo- controlled trial and concluded that the evidence  for the use of haloperidol to treat delirium in ICU  patients was sparse and inconclusive. We con­ ducted the Agents Intervening against Delirium in  the Intensive Care Unit (AID-ICU) trial to investi­ gate whether treatment with haloperidol would  lead to a greater number of days alive and out of  the,2,19,0.8137445449829102
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf," 50% of pa­ tients being treated in the intensive care unit (ICU)  and is associated with increased morbidity and  mortality.3-7 Haloperidol, a typical antipsychotic compound,  continues to be the most frequently used agent to  treat delirium in ICU patients. Results of an in­ ternational inception-cohort study that were pub­ lished in 2018 showed that approximately half the  ICU patients with delirium received",2,17,0.8137445449829102
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf," evidence demonstrating that haloper- idol reduces the incidence or duration of delirium in ICU patients, the use of haloperidol as a first-line pharmacologic agent for ICU delirium was supported by the previous practice guidelines, published in 2002.5 However, the Pain, Agitation, and Delirium (PAD) guidelines, recently released by the Amer- ican College of Critical Care Medicine and the Society of Crit- ical Care Medicine, downgraded their",1,6,0.8128204345703125
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf,"n engl j med 387;26  nejm.org  december 29, 2022 2427 Haloperidol for Delirium in ICU Patients vestigators and clinicians at the trial sites to  screen all the patients fulfilling the inclusion  criteria for enrollment in the trial. Patients could  be assessed for eligibility throughout the entire  ICU stay. Randomization and Blinding Eligible patients were randomly assigned in a 1:1  ratio to receive haloperidol",3,31,0.8097615242004395
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RAEATICU.pdf," after quetiapine administration [12]. Additionally, in a recent retrospective study of 113 critically ill patients with hypoactive deliri- um, Michaud and colleagues reported that quetiapine reduced the dura- tion of delirium when compared to standard care alone [13]. The goal of this retrospective study was to compare outcomes of critically ill patients with delirium who were managed with or without antipsychotics. To our knowledge, this is the ﬁr",1,13,0.8096189498901367
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf, of early physical and occupational therapy (PT/OT) on functional outcomes in mechanically ventilated patients in the ICU.28 This study demonstrated that the early administra- tion of PT and OT improved functional outcomes and reduced the incidence and duration of ICU delirium. The 2013 updated PAD guidelines strongly support early mobilization whenever feasible for the prevention of delirium.6 Diagnosis An accurate and timely diagnosis of delirium in ICU patients is key to effectively treating delirium;,3,35,0.8073644638061523
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf, pub­ lished in 2018 showed that approximately half the  ICU patients with delirium received haloperidol.8  The use of haloperidol is not supported by clini­ cal practice guidelines because evidence of its  effect is limited.1 A recent systematic review9 of  trials comparing haloperidol with other pharma­ cologic interventions for the treatment of deliri­ um in ICU patients identified only one placebo- controlled trial and concluded that the evidence ,2,18,0.8063688278198242
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",AID-ICU.pdf," with haloperidol would  lead to a greater number of days alive and out of  the hospital than placebo; other clinically im­ portant outcomes in ICU patients with delirium  were also evaluated. Methods Trial Design and Oversight This was a multicenter, blinded, parallel-group,  placebo-controlled clinical trial with centralized  randomization. Patient screening was performed  between June 14, 2018, and April 9, 2022, at 18  general ICUs in Denmark, Finland",2,20,0.8063688278198242
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf," in patients receiving haloperidol as opposed to the olanzapine group (6 patients vs 0 patient). This study con- cluded that olanzapine is a safe alternative to haloperidol in ICU patients with delirium. However, this study design was limited by its small sample size, uneven distribution of study drugs between 2 treatment groups due to the odd/even day ran- domization, lack of blinding, and no placebo group. Queti",5,67,0.8063688278198242
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RUSGATICUD.pdf,", patients in the quetiapine group experienced more somnolence than those treated with placebo (22% vs 11%, P ¼ .66). This study suggested that treatment with quickly escalating doses of quetiapine may reduce the duration of delir- ium and agitation in ICU patients with delirium. The limita- tions of this study included a small sample size, low external validity due to its restrictive inclusion/exclusion criteria, and the use",6,84,0.8063688278198242
25,"Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?",RAEATICU.pdf,"intani A, Truman B, et al. Delirium as a predictor of mortality in mechan- ically ventilated patients in the intensive care unit. JAMA 2004;291(14):1753–62. [4] Ouimet S, Kavanagh BP, Gottfried SB, et al. Incidence, risk factors, and consequences of ICU delirium. Int Care Med 2007;33:66–73. [5] Mehta S, Cook D",5,85,0.8039312362670898
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,ETSDMV.pdf," BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill  patients. New Engl J Med 2019; 380:2506–2517. [PubMed: 31112380] ▪▪ Large multicenter  randomized controlled trial comparing early dexmedetomidine to usual care. Although no  difference was in the primary outcome of 90-day mortality, a majority of patients in both groups  failed to receive the targeted level of light",8,84,0.8822643756866455
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,DDMLSMVICP.pdf,"Clinical Investigations Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients* Yahya Shehabi, FCICM, EMBA; Richard R. Riker, MD; Paula M. Bokesch, MD; Wayne Wisemandle, MA; Ayumi Shintani, PhD, MPH; E. Wesley Ely, MD, MPH; for the SEDCOM (Safety and Efﬁcacy of Dexmedetomidine Compared With",1,1,0.8604984283447266
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,HDDSICU.pdf, I 741 theannals.com Table 1. The Ohio State University Medical Center Dexmedetomidine Use Criteria 1. Restricted use for ICU patients for management of acute agitation secondary to delirium or alcohol/drug withdrawal and for patients who are mechanically ventilated during routine care in the ICU; not approved for procedural sedation in nonmechanically ventilat- ed patients.  2. MAP must be >65 mm Hg and heart rate must be >,2,27,0.8547594547271729
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf," delirium occurred with greater frequency in the propofol  cohort compared with the dexmedetomidine cohort, but the  absolute difference was smaller than what was observed in  SEDCOM (9.7% vs 4.6% respectively, P = 0.056).4 In  SPICE III, patients in the dexmedetomidine group had 1  more coma or delirium-free day (24 days [IQR = 11-26])  compared",4,47,0.8524308204650879
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf," the dexmedetomidine cohort compared with the  usual care cohort (9.6% vs 1.8%, respectively; P < 0.0001).5  Consistent with previous studies, bradycardia and hypoten- sion were the most frequent adverse events in the dexme- detomidine group. However, the rates of both hypotension  and bradycardia observed in the dexmedetomidine group in  SPICE III were lower than in previous trials",3,40,0.8524308204650879
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,HDDSICU.pdf," more days alive without coma and more time at the targeted lev- el of sedation. The MENDS trial also expanded the amount of reported information regarding the safety of dexmedeto- midine across a wide dosing range. Published 2 years later, High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety G Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J",1,6,0.8480937480926514
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,DIICU.pdf," GABA receptors, may prove to be an alternative sedative agent that is less likely to cause delirium. In a preliminary report of an unblinded, randomized trial conducted in postoperative cardiac surgical patients, Maldonado and colleagues [68] described a significant reduction in the incidence of delirium associated with dexmedetomidine; 8% of patients sedated with dex- medetomidine at sternal closure developed delirium as compared with 50% of patients sedated with",7,93,0.8455383777618408
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,HDDSICU.pdf,". Results showed that patients treated with dexmedetomidine experienced a comparable level of sedation, spent less time on the ventilator, experi- enced less delirium, and developed less tachycardia and hypertension.  Both the MENDS and SEDCOM trials used higher dexmedetomidine doses for longer durations than those previously studied and showed similar efficacy and safety outcomes.5,11 However, neither study assessed the impact of doses greater than 0.7",2,15,0.8435654640197754
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf," regarding use of dexmedetomidine in the ICU. SPICE III The SPICE III trial compared the use of dexmedetomidine  with usual care (propofol or midazolam or a combination  of the two) for sedation therapy in mechanically venti- lated patients.5 This open-label, randomized trial enrolled  3904 patients (dexmedetomidine: n = 1948; usual care:  n = 1956). The primary outcome",1,6,0.8406720161437988
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.8399920463562012
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf,"	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with  dexmedetomidine in critically ill patients. N Engl J Med.  2019;380:2506-2517. doi:10.1056/NEJMoa1904710 	 6.	 Pandharipande PP, Sanders RD, Girard TD, et al. Effect of  dexmedetomidine versus lorazepam on outcome in",5,62,0.8399920463562012
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.8399920463562012
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.8384871482849121
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf," popularity for use in the intensive care unit over the past 20 years.  Guidelines recommend dexmedetomidine as a first-line agent to achieve light sedation in mechanically ventilated adults.  Recently, the SPICE III (Sedation Practice in Intensive Care Evaluation III) trial was published. This was a randomized controlled  trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical  ventilation. The results of this trial have both validated",1,13,0.8384623527526855
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf,"etomidine in sepsis have associated use of the  agent with lower mortality.6,7 Thus, the choice of mortality  as the primary outcome of SPICE III is reasonable. Finally,  SPICE III was the first randomized controlled trial to exam- ine the effects of dexmedetomidine sedation for up to 180  days postrandomization. Sedation Sedation goals in previous trials did not allow investiga- tors to target deep sedation.2-",3,25,0.838376522064209
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,HDDSICU.pdf,"the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared to Midazolam) trial5 allowed a maximum dexmedetomidine dose of 1.4 µg/kg/h and assessed the per- centage of time spent at goal sedation according to the Richmond Agitation and Sedation Scale (RASS)12 when compared to midazolam. Results showed that patients treated with dexmedetomidine experienced a comparable level of sedation,",2,14,0.8365378379821777
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,HDDSICU.pdf," Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J Pell Critical Care Author information provided at end of text. BACKGROUND: Dexmedetomidine is an α2-receptor agonist used for sedation in the intensive care unit (ICU). Although dexmedetomidine is labeled for sedation in critically ill patients at doses up to 0.7 µg/kg/h, recent studies have used more liberal dosing regimens",1,7,0.8365378379821777
26,Is there more adverse events in ICU patients who recieved early dexmedetomidine?,RDSCI.pdf,"https://doi.org/10.1177/1060028019890672 Annals of Pharmacotherapy 2020, Vol. 54(5) 504­–508 © The Author(s) 2019 Article reuse guidelines:  sagepub.com/journals-permissions DOI: 10.1177/1060028019890672 journals.sagepub.com/home/aop Commentary Introduction Dexmedetomidine, a central α-2 agonist medication,",1,1,0.8365378379821777
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.9243552684783936
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf,"	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with  dexmedetomidine in critically ill patients. N Engl J Med.  2019;380:2506-2517. doi:10.1056/NEJMoa1904710 	 6.	 Pandharipande PP, Sanders RD, Girard TD, et al. Effect of  dexmedetomidine versus lorazepam on outcome in",5,62,0.9098989963531494
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.9098989963531494
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ETSDMV.pdf," BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill  patients. New Engl J Med 2019; 380:2506–2517. [PubMed: 31112380] ▪▪ Large multicenter  randomized controlled trial comparing early dexmedetomidine to usual care. Although no  difference was in the primary outcome of 90-day mortality, a majority of patients in both groups  failed to receive the targeted level of light",8,84,0.9098989963531494
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.9098989963531494
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",DDS.pdf,"2162–8. 8. Reeves RA, Boer WH, DeLeve L, Leenen FH. Nonselective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man. Clin Pharmacol Ther. 1984;35:461–6. 9. Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;",3,32,0.903374195098877
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf," popularity for use in the intensive care unit over the past 20 years.  Guidelines recommend dexmedetomidine as a first-line agent to achieve light sedation in mechanically ventilated adults.  Recently, the SPICE III (Sedation Practice in Intensive Care Evaluation III) trial was published. This was a randomized controlled  trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical  ventilation. The results of this trial have both validated",1,13,0.9017841815948486
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf,"  doi:10.1007/s40265-015-0419-5 	12.	 Jones GM, Murphy CV, Gerlach AT, Goodman EM, Pell LJ.  High-dose dexmedetomidine for sedation in the intensive  care unit: an evaluation of clinical efficacy and safety. Ann  Pharmacother. 2011;45:740-747. doi:10.1345/aph.1P726 	13.	 Nelson KM",5,68,0.9005365371704102
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",HDDSICU.pdf," more days alive without coma and more time at the targeted lev- el of sedation. The MENDS trial also expanded the amount of reported information regarding the safety of dexmedeto- midine across a wide dosing range. Published 2 years later, High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety G Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J",1,6,0.9005365371704102
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ETSDMV.pdf,"PubMed: 11296183]  16. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus  propofol with daily interruption in mechanically ventilated patients*. Crit Care Med 2006;  34:1326–1332. [PubMed: 16540958]  17. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs",7,69,0.8857941627502441
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",EDvsLSMENDS.pdf," subgroup analysis of septic vs non-septic patients from the MENDS double-blind  randomized controlled trial, adult medical/surgical mechanically ventilated patients were randomized to receive  dexmedetomidine-based or lorazepam-based sedation for up to 5 days. Delirium and other clinical outcomes were  analyzed comparing sedation groups, adjusting for clinically relevant covariates as well as assessing interactions  between sedation group and sepsis. Results: Of",1,5,0.8827502727508545
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf,"508	 Annals of Pharmacotherapy 54(5) 	 3.	 Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs  midazolam for sedation of critically ill patients: a randomized  trial. JAMA. 2009;301:489-499. doi:10.1001/jama.2009.56 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al",5,60,0.8822376728057861
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",SEDCOM.pdf,"). DEXMEDETOMIDINE VS MIDAZOLAM FOR SEDATION OF CRITICALLY ILL PATIENTS 492 JAMA, February 4, 2009—Vol 301, No. 5 (Reprinted) ©2009 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Duke Medical Center Library user on 02/13/2025",4,70,0.8810105323791504
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf,"etomidine in sepsis have associated use of the  agent with lower mortality.6,7 Thus, the choice of mortality  as the primary outcome of SPICE III is reasonable. Finally,  SPICE III was the first randomized controlled trial to exam- ine the effects of dexmedetomidine sedation for up to 180  days postrandomization. Sedation Sedation goals in previous trials did not allow investiga- tors to target deep sedation.2-",3,25,0.8769176006317139
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",SPICE-III.pdf,"  populations.17,18 Hypotension and bradycardia are  common side effects.5,6 We conducted a multinational, open-label,  randomized, controlled trial (Sedation Practice  in Intensive Care Evaluation [SPICE] III) to inves- tigate the effect of using dexmedetomidine as  the primary and, if possible, sole agent for early  sedation among patients receiving ventilatory  support. Our hypothesis was that the use",2,16,0.8734679222106934
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ETSDMV.pdf,"▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to prevent ICU delirium. Notable for being one of the few interventions shown  to prevent ICU delirium. 30. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and  ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmed",8,82,0.8703618049621582
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",RDSCI.pdf," Morimoto T, et al. Effect of dex- medetomidine on mortality and ventilator-free days in patients  requiring mechanical ventilation with sepsis: a randomized  clinical trial. JAMA. 2017;317:1321-1328. doi:10.1001/ jama.2017.2088 	 8.	 Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care  sedation predicts long-term mortality",5,64,0.8703618049621582
27,"Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?",ETSDMV.pdf," BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs  lorazepamon acutebrain dysfunction in mechanically ventilated patients: the MENDS Randomized  Controlled Trial. JAMA 2007; 298:2644–2653. [PubMed: 18073360]  18. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ",7,70,0.8701419830322266
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ETSDMV.pdf," BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs  lorazepamon acutebrain dysfunction in mechanically ventilated patients: the MENDS Randomized  Controlled Trial. JAMA 2007; 298:2644–2653. [PubMed: 18073360]  18. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ",7,70,0.9377005100250244
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,SEDCOM.pdf,"). DEXMEDETOMIDINE VS MIDAZOLAM FOR SEDATION OF CRITICALLY ILL PATIENTS 492 JAMA, February 4, 2009—Vol 301, No. 5 (Reprinted) ©2009 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Duke Medical Center Library user on 02/13/2025",4,70,0.9336581230163574
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf,"508	 Annals of Pharmacotherapy 54(5) 	 3.	 Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs  midazolam for sedation of critically ill patients: a randomized  trial. JAMA. 2009;301:489-499. doi:10.1001/jama.2009.56 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al",5,60,0.9293241500854492
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ETSDMV.pdf," Jakob SM, et al. Dexmedetomidine versus propofol/midazolam for  long-term sedation during mechanical ventilation. Intensive Care Med 2009; 35:282–290.  [PubMed: 18795253]  24. Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically  ill adults: a prospective, multicenter study. Crit Care 2009; 13",8,76,0.9183874130249023
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ETSDMV.pdf,"22. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs Midazolam or propofol for  sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012;  307:1151–1160. [PubMed: 22436955]  23. Ruokonen E, Parviainen I, Jakob SM, et al. Dexmedetomidine versus propofol/midazol",8,75,0.916161298751831
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf," 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine  vs midazolamor propofol for sedation during prolonged  mechanical ventilation: two randomized controlled trials.  JAMA. 2012;307:1151-1160. doi:10.1001/jama.2012.304 	 5.	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with",5,61,0.916161298751831
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.8950529098510742
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf," popularity for use in the intensive care unit over the past 20 years.  Guidelines recommend dexmedetomidine as a first-line agent to achieve light sedation in mechanically ventilated adults.  Recently, the SPICE III (Sedation Practice in Intensive Care Evaluation III) trial was published. This was a randomized controlled  trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical  ventilation. The results of this trial have both validated",1,13,0.8819403648376465
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf," study showed that dexmedetomidine was  associated with lower prevalence of delirium relative to  midazolam (54% vs 76.6%, P < 0.01).3 However, preva- lence of delirium was similar between midazolam and dex- medetomidine in the MIDEX trial.4 In the PRODEX trial,  delirium occurred with greater frequency in the propofol  cohort compared with the dexmedet",4,46,0.8813085556030273
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,HDDSICU.pdf,"the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared to Midazolam) trial5 allowed a maximum dexmedetomidine dose of 1.4 µg/kg/h and assessed the per- centage of time spent at goal sedation according to the Richmond Agitation and Sedation Scale (RASS)12 when compared to midazolam. Results showed that patients treated with dexmedetomidine experienced a comparable level of sedation,",2,14,0.877892017364502
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,DDS.pdf,"2162–8. 8. Reeves RA, Boer WH, DeLeve L, Leenen FH. Nonselective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man. Clin Pharmacol Ther. 1984;35:461–6. 9. Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;",3,32,0.8766300678253174
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,DDMLSMVICP.pdf,"EDCOM (Safety and Efﬁcacy of Dexmedetomidine Compared With Midazolam) Study Group D elirium is a recognized organ dysfunction complicating critical illness and consti- tutes a major challenge to in- tensive care practitioners worldwide (1– 3). In a survey of critical care clinicians, 85% of responders perceived intensive care unit (ICU) delirium as a signiﬁcant factor in prolonged ventilation",1,2,0.8760578632354736
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,EDvsLSMENDS.pdf,"ist, provided safe and effi- cacious sedation in critically ill MV patients, with signifi- cant improvement in brain organ dysfunction (delirium and coma) compared with the benzodiazepine, loraze- pam (LZ). The principal findings from the MENDS trial were recently corroborated by the Safety and Efficacy of Dexmedetomidine Compared With Midazolam (SED- COM) trial of 366 critically ill patients, which showed a",2,18,0.8760578632354736
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.8749661445617676
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,ETSDMV.pdf," BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill  patients. New Engl J Med 2019; 380:2506–2517. [PubMed: 31112380] ▪▪ Large multicenter  randomized controlled trial comparing early dexmedetomidine to usual care. Although no  difference was in the primary outcome of 90-day mortality, a majority of patients in both groups  failed to receive the targeted level of light",8,84,0.8749661445617676
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.8749661445617676
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf,"	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with  dexmedetomidine in critically ill patients. N Engl J Med.  2019;380:2506-2517. doi:10.1056/NEJMoa1904710 	 6.	 Pandharipande PP, Sanders RD, Girard TD, et al. Effect of  dexmedetomidine versus lorazepam on outcome in",5,62,0.8749661445617676
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,HDDSICU.pdf," more days alive without coma and more time at the targeted lev- el of sedation. The MENDS trial also expanded the amount of reported information regarding the safety of dexmedeto- midine across a wide dosing range. Published 2 years later, High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety G Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J",1,6,0.8696367740631104
28,Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?,RDSCI.pdf,"  doi:10.1007/s40265-015-0419-5 	12.	 Jones GM, Murphy CV, Gerlach AT, Goodman EM, Pell LJ.  High-dose dexmedetomidine for sedation in the intensive  care unit: an evaluation of clinical efficacy and safety. Ann  Pharmacother. 2011;45:740-747. doi:10.1345/aph.1P726 	13.	 Nelson KM",5,68,0.8696367740631104
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.8668718338012695
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf," BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill  patients. New Engl J Med 2019; 380:2506–2517. [PubMed: 31112380] ▪▪ Large multicenter  randomized controlled trial comparing early dexmedetomidine to usual care. Although no  difference was in the primary outcome of 90-day mortality, a majority of patients in both groups  failed to receive the targeted level of light",8,84,0.863591194152832
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.863591194152832
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.863591194152832
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,RDSCI.pdf,"	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with  dexmedetomidine in critically ill patients. N Engl J Med.  2019;380:2506-2517. doi:10.1056/NEJMoa1904710 	 6.	 Pandharipande PP, Sanders RD, Girard TD, et al. Effect of  dexmedetomidine versus lorazepam on outcome in",5,62,0.863591194152832
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,DDS.pdf,"2162–8. 8. Reeves RA, Boer WH, DeLeve L, Leenen FH. Nonselective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man. Clin Pharmacol Ther. 1984;35:461–6. 9. Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;",3,32,0.846172571182251
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,SEDCOM.pdf,"). DEXMEDETOMIDINE VS MIDAZOLAM FOR SEDATION OF CRITICALLY ILL PATIENTS 492 JAMA, February 4, 2009—Vol 301, No. 5 (Reprinted) ©2009 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Duke Medical Center Library user on 02/13/2025",4,70,0.8445067405700684
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,RDSCI.pdf,"508	 Annals of Pharmacotherapy 54(5) 	 3.	 Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs  midazolam for sedation of critically ill patients: a randomized  trial. JAMA. 2009;301:489-499. doi:10.1001/jama.2009.56 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al",5,60,0.8406023979187012
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,HDDSICU.pdf," more days alive without coma and more time at the targeted lev- el of sedation. The MENDS trial also expanded the amount of reported information regarding the safety of dexmedeto- midine across a wide dosing range. Published 2 years later, High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety G Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J",1,6,0.8377716541290283
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,RDSCI.pdf,"  doi:10.1007/s40265-015-0419-5 	12.	 Jones GM, Murphy CV, Gerlach AT, Goodman EM, Pell LJ.  High-dose dexmedetomidine for sedation in the intensive  care unit: an evaluation of clinical efficacy and safety. Ann  Pharmacother. 2011;45:740-747. doi:10.1345/aph.1P726 	13.	 Nelson KM",5,68,0.8377716541290283
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf," BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs  lorazepamon acutebrain dysfunction in mechanically ventilated patients: the MENDS Randomized  Controlled Trial. JAMA 2007; 298:2644–2653. [PubMed: 18073360]  18. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ",7,70,0.8363373279571533
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,DDMLSMVICP.pdf,"Clinical Investigations Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients* Yahya Shehabi, FCICM, EMBA; Richard R. Riker, MD; Paula M. Bokesch, MD; Wayne Wisemandle, MA; Ayumi Shintani, PhD, MPH; E. Wesley Ely, MD, MPH; for the SEDCOM (Safety and Efﬁcacy of Dexmedetomidine Compared With",1,1,0.8318524360656738
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf,"▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to prevent ICU delirium. Notable for being one of the few interventions shown  to prevent ICU delirium. 30. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and  ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmed",8,82,0.8295528888702393
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,RDSCI.pdf," Morimoto T, et al. Effect of dex- medetomidine on mortality and ventilator-free days in patients  requiring mechanical ventilation with sepsis: a randomized  clinical trial. JAMA. 2017;317:1321-1328. doi:10.1001/ jama.2017.2088 	 8.	 Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care  sedation predicts long-term mortality",5,64,0.8295528888702393
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf,"PubMed: 11296183]  16. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus  propofol with daily interruption in mechanically ventilated patients*. Crit Care Med 2006;  34:1326–1332. [PubMed: 16540958]  17. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs",7,69,0.8225390911102295
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,ETSDMV.pdf,"PubMed: 26975647]  29. Skrobik Y, Duprey MS, Hill NS, et al. Low-dose nocturnal dexmedetomidine prevents ICU  delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med 2018; 197:1147– 1156. [PubMed: 29498534] ▪▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to",8,81,0.818795919418335
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,SMDLTSWCI.pdf,"idine is becoming increasingly popular due to its  “cooperative sedation” and opioid-sparing  properties,  and the absence of respiratory depression. Neverthe- less, the SPICE III trial [28] reported that early use of  dexmedetomidine in mechanically ventilated patients  did not improve outcomes more than usual care. Most  Table 1  Baseline characteristics of patients in intention-to-treat analysis ICU, Intensive Care",6,68,0.8186910152435303
29,Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?,DDS.pdf," a systematic review. Health Technol Assess. 2016;20:1–118. 11. Reade MC, Eastwood GM, Bellomo R, Bailey M, Bersten A, Cheung B, Davies A, Delaney A, Ghosh A, van Haren F, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA. 2016;315:",3,34,0.817704439163208
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf,"PubMed: 11296183]  16. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus  propofol with daily interruption in mechanically ventilated patients*. Crit Care Med 2006;  34:1326–1332. [PubMed: 16540958]  17. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs",7,69,0.8911316394805908
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf," popularity for use in the intensive care unit over the past 20 years.  Guidelines recommend dexmedetomidine as a first-line agent to achieve light sedation in mechanically ventilated adults.  Recently, the SPICE III (Sedation Practice in Intensive Care Evaluation III) trial was published. This was a randomized controlled  trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical  ventilation. The results of this trial have both validated",1,13,0.8868303298950195
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.8863348960876465
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf,"etomidine in sepsis have associated use of the  agent with lower mortality.6,7 Thus, the choice of mortality  as the primary outcome of SPICE III is reasonable. Finally,  SPICE III was the first randomized controlled trial to exam- ine the effects of dexmedetomidine sedation for up to 180  days postrandomization. Sedation Sedation goals in previous trials did not allow investiga- tors to target deep sedation.2-",3,25,0.8827114105224609
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",DDS.pdf,"2162–8. 8. Reeves RA, Boer WH, DeLeve L, Leenen FH. Nonselective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man. Clin Pharmacol Ther. 1984;35:461–6. 9. Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;",3,32,0.8781692981719971
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",DDS.pdf," a systematic review. Health Technol Assess. 2016;20:1–118. 11. Reade MC, Eastwood GM, Bellomo R, Bailey M, Bersten A, Cheung B, Davies A, Delaney A, Ghosh A, van Haren F, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA. 2016;315:",3,34,0.8743259906768799
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf,". Effect of dexmedetomidine added to standard care on  ventilator-free time in patients with agitated delirium: a randomized clinical trialdexmedetomidine  plus standard care in patients with agitated deliriumdexmedetomidine plus standard care in  patients with agitated delirium. JAMA 2016; 315:1460–1468. [PubMed: 26975647]  29. Skrobik Y, Duprey MS, Hill",8,80,0.8743259906768799
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",EDvsLSMENDS.pdf," subgroup analysis of septic vs non-septic patients from the MENDS double-blind  randomized controlled trial, adult medical/surgical mechanically ventilated patients were randomized to receive  dexmedetomidine-based or lorazepam-based sedation for up to 5 days. Delirium and other clinical outcomes were  analyzed comparing sedation groups, adjusting for clinically relevant covariates as well as assessing interactions  between sedation group and sepsis. Results: Of",1,5,0.8730263710021973
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.8683409690856934
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.8683409690856934
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf,"	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with  dexmedetomidine in critically ill patients. N Engl J Med.  2019;380:2506-2517. doi:10.1056/NEJMoa1904710 	 6.	 Pandharipande PP, Sanders RD, Girard TD, et al. Effect of  dexmedetomidine versus lorazepam on outcome in",5,62,0.8683409690856934
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf," BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill  patients. New Engl J Med 2019; 380:2506–2517. [PubMed: 31112380] ▪▪ Large multicenter  randomized controlled trial comparing early dexmedetomidine to usual care. Although no  difference was in the primary outcome of 90-day mortality, a majority of patients in both groups  failed to receive the targeted level of light",8,84,0.8683409690856934
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",SPICE-III.pdf,"  populations.17,18 Hypotension and bradycardia are  common side effects.5,6 We conducted a multinational, open-label,  randomized, controlled trial (Sedation Practice  in Intensive Care Evaluation [SPICE] III) to inves- tigate the effect of using dexmedetomidine as  the primary and, if possible, sole agent for early  sedation among patients receiving ventilatory  support. Our hypothesis was that the use",2,16,0.8648793697357178
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",HDDSICU.pdf," more days alive without coma and more time at the targeted lev- el of sedation. The MENDS trial also expanded the amount of reported information regarding the safety of dexmedeto- midine across a wide dosing range. Published 2 years later, High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety G Morgan Jones, Claire V Murphy, Anthony T Gerlach, Erin M Goodman, and Lindsay J",1,6,0.8609583377838135
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf,"  doi:10.1007/s40265-015-0419-5 	12.	 Jones GM, Murphy CV, Gerlach AT, Goodman EM, Pell LJ.  High-dose dexmedetomidine for sedation in the intensive  care unit: an evaluation of clinical efficacy and safety. Ann  Pharmacother. 2011;45:740-747. doi:10.1345/aph.1P726 	13.	 Nelson KM",5,68,0.8609583377838135
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf," BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs  lorazepamon acutebrain dysfunction in mechanically ventilated patients: the MENDS Randomized  Controlled Trial. JAMA 2007; 298:2644–2653. [PubMed: 18073360]  18. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ",7,70,0.8583214282989502
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",ETSDMV.pdf,"ard TD, et al. Effect of dexmedetomidine versus lorazepam on  outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized  controlled trial. Crit Care 2010; 14:R38. [PubMed: 20233428]  28. Reade MC, Eastwood GM, Bellomo R, et al. Effect of dexmedetomidine added to standard care on  ventilator-free time",8,79,0.8567578792572021
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf," for use in mechanically ventilated patients in the  intensive care unit (ICU). The appealing qualities of dex- medetomidine include the lack of respiratory depression  and inability to yield deep sedation, which current sedation  guidelines recommend to avoid.1 Several randomized con- trolled trials have been conducted comparing dexmedeto- midine monotherapy sedation with sedation using other  agents, which are summarized in Table 1.2-4 Current sedation guidelines recommend use of prop",1,3,0.8560185432434082
30,"At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?",RDSCI.pdf,"508	 Annals of Pharmacotherapy 54(5) 	 3.	 Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs  midazolam for sedation of critically ill patients: a randomized  trial. JAMA. 2009;301:489-499. doi:10.1001/jama.2009.56 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al",5,60,0.8544683456420898
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,ESCPARDS.pdf," Med 2006;354:1671-84. Copyright © 2006 Massachusetts Medical Society. Background Persistent acute respiratory distress syndrome (ARDS) is characterized by excessive  fibroproliferation, ongoing inflammation, prolonged mechanical ventilation, and a  substantial risk of death. Because previous reports suggested that corticosteroids  may improve survival, we performed a multicenter, randomized controlled trial of  corticosteroids in patients with persistent ARDS. Methods We randomly assigned 180 patients with ARDS of at",1,5,0.8996801376342773
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,ESCPARDS.pdf,"prednisolone did not increase  the rate of infectious complications but was associated with a higher rate of neuro- muscular weakness. Conclusions These results do not support the routine use of methylprednisolone for persistent  ARDS despite the improvement in cardiopulmonary physiology. In addition, start- ing methylprednisolone therapy more than two weeks after the onset of ARDS may  increase the risk of death. (ClinicalTrials.gov number, NCT00295269",1,10,0.8511941432952881
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,TOF-ARDS.pdf,"/kg of predicted body weight  (PBW) [2], a short course of neuromuscular blocking  agents (NMBAs) [3] in severely hypoxemic patients, and  the use of prone positioning (PP) [4]. NMBAs are fre- quently used in the most severe forms of ARDS [1]. They  are the only pharmacologic intervention that has been  shown to improve the prognosis of moderate-to-severe  ARDS",1,12,0.8494284152984619
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,OSCILLATE.pdf,"DS.23-26 We therefore compared HFOV  with a conventional ventilation strategy that used  low tidal volumes and high levels of PEEP in pa- tients with new-onset, moderate-to-severe ARDS. Methods Study Oversight For the pilot phase of the study, we enrolled pa- tients at 11 centers in Canada and 1 in Saudi  Arabia from July 2007 through June 2008; for the  main trial, we enrolled patients at the same cen- ters",2,25,0.8492999076843262
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8449037075042725
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,BMIMSARDS.pdf,"Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial Haytham Tlayjeh, Yaseen M Arabi, Niall D Ferguson, Qi Zhou, Francois Lamontagne, Alejandro Arroliga, Valerie Danesh, Guillermo Dominguez-Cherit, Edgar Jimenez, Adam Mullaly, Brandon Staub, and Maureen O Meade; for the Canadian Critical Care Trials Group BACK",1,1,0.8410799503326416
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.8391909599304199
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,RARDS.pdf," ARDSnet trials showed no difference between patients with moderate–severe and mild–moderate ARDS in terms of mortality, even though there were differences in rapid resolution of ARDS, ventilator-free days, and ICU-free days. Author disclosures are available with the text of this article at www.atsjournals.org. Acknowledgment: The authors are grateful to the investigators of ARDS Network (ARDSNet) trials for collecting the data on which this analysis was based,",3,42,0.8385140895843506
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8352704048156738
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8323330879211426
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,BMIMSARDS.pdf," THE RELATED EDITORIAL ON PAGE 1173 12 mL/kg did not show any difference in outcome between obese and normal weight subjects.7 Other studies have suggested better survival for obese subjects with ARDS compared to subjects with normal weight.5 Studies have also shown that being underweight is associated with in- creased mortality in subjects with ARDS.8 The Oscillation for ARDS Treated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate",2,15,0.830254077911377
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,LSPA.pdf,"–31 or  high PEEP strategies32,33 that are often employed for management of ARDS. However, deep  sedation is required in patients with ARDS who receive neuromuscular blockage to ensure  patients do not consciously experience paralysis.34,35 Neuromuscular blockage is sometimes  used in severe ARDS based on results of a multicenter trial in France that showed improved  mortality with 48 hours of neuromuscular blockage in patients who have severe",3,23,0.826880693435669
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,EDPMARDSLPMV.pdf," this result may be due to the wide range of VT used across the trials included. To try to answer this question, we investigated ΔPrs from two trials [4, 5] in which strict lung- protective mechanical ventilation, in particular 6 ml/kg predicted body weight VT, was applied to patients with ARDS. Our working hypothesis was that ΔPrs was asso- ciated with death, just like compliance (Crs) or Pplat,rs. Methods This is a",2,18,0.8249711990356445
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,CEIIUPPSARDS.pdf, Setting: Intensive care units that care for patients with ARDS. Subjects: Patients with moderate to severe ARDS. For reprints : Corresponding Author: Cameron M Baston. 3400 Spruce St. Philadelphia PA 19104. cbass@alum.mit.edu  +12159133239.  The work was performed at the University of Pennsylvania Declaration of Conflict of Interest: The authors have disclosed that they do not have any conflicts of interest. HHS Public Access Author manuscript Crit,1,6,0.8249711990356445
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,APV.pdf," ventilation variables have to be properly adjusted during ventilatory therapy, which generally requires continuous care from clinical staff, es- pecially for patients with severe ARDS. To minimize the workload of daily clinical practice and to maintain the standard protocol of protective ventilation, we introduce automatic control of ventilation as a concept for the treatment. In this article, we describe a strategy of auto- matic ventilation in ARDS patients, including continu- ous monitoring of regional ventilation at thoracic cavity using electrical impedance",2,18,0.8229014873504639
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,CEIIUPPSARDS.pdf,"ri F, Pugliese F, Ranieri VM. The Role of Rescue Therapies in the Treatment of Severe  ARDS. Respiratory care 2018;63(1):92–101. [PubMed: 29066591]  9. Li X, Scales DC, Kavanagh BP. Unproven and Expensive Before Proven and Cheap - Extracorporeal  Membrane Oxygenation vs. Prone Position in ARDS. American journal of",8,73,0.8202707767486572
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,BMIMSARDS.pdf,"ated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate-to-severe ARDS to high-frequency oscillatory ventilation (HFOV) or conventional mechani- cal ventilation. The purpose of this sub-analysis of the OSCILLATE trial was to examine the association of BMI on mortality and relevant processes of care of subjects withmoderate-to-severeARDS.Wehypothesizedthatmor- tality differs across different BMI strata and",2,16,0.8174688816070557
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,BMIMSARDS.pdf," associations at both extremes of BMI. Conclusions In the OSCILLATE Trial, there was no difference in adjusted hospital mortality across all BMI strata in sub- jects with moderate-to-severe ARDS. Processes of care were not different between the BMI strata except for higher daily doses of fentanyl as BMI increased. ACKNOWLEDGMENTS We acknowledge Michael Chasse and Martin Albert for their critical review of the manuscript. REFERENCES 1. Ogden CL,",7,92,0.8174688816070557
31,Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate? ,BMIMSARDS.pdf,". It also includes subjects managed with HFOV, a group in which the relation of BMI and outcomes has not been studied before. Methods Study Subjects and Sample The OSCILLATE trial randomized 548 subjects with moderate-to-severe ARDS to HFOV or conventional ven- tilation from 39 ICUs in Canada, the United States, Saudi Arabia, Chile, and India.9 Institutional review boards of the participating centers approved the study. Patients were eligible for inclusion if they had",2,18,0.8174688816070557
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,BMIMSARDS.pdf," THE RELATED EDITORIAL ON PAGE 1173 12 mL/kg did not show any difference in outcome between obese and normal weight subjects.7 Other studies have suggested better survival for obese subjects with ARDS compared to subjects with normal weight.5 Studies have also shown that being underweight is associated with in- creased mortality in subjects with ARDS.8 The Oscillation for ARDS Treated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate",2,15,0.8844783306121826
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,BMIMSARDS.pdf,"Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial Haytham Tlayjeh, Yaseen M Arabi, Niall D Ferguson, Qi Zhou, Francois Lamontagne, Alejandro Arroliga, Valerie Danesh, Guillermo Dominguez-Cherit, Edgar Jimenez, Adam Mullaly, Brandon Staub, and Maureen O Meade; for the Canadian Critical Care Trials Group BACK",1,1,0.8816728591918945
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,RARDS.pdf," ARDSnet trials showed no difference between patients with moderate–severe and mild–moderate ARDS in terms of mortality, even though there were differences in rapid resolution of ARDS, ventilator-free days, and ICU-free days. Author disclosures are available with the text of this article at www.atsjournals.org. Acknowledgment: The authors are grateful to the investigators of ARDS Network (ARDSNet) trials for collecting the data on which this analysis was based,",3,42,0.8680810928344727
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,ESCPARDS.pdf,"prednisolone did not increase  the rate of infectious complications but was associated with a higher rate of neuro- muscular weakness. Conclusions These results do not support the routine use of methylprednisolone for persistent  ARDS despite the improvement in cardiopulmonary physiology. In addition, start- ing methylprednisolone therapy more than two weeks after the onset of ARDS may  increase the risk of death. (ClinicalTrials.gov number, NCT00295269",1,10,0.867743968963623
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,CEIIUPPSARDS.pdf,"1253–1263. [PubMed: 28459336]  6. Bein T, Grasso S, Moerer O, et al. The standard of care of patients with ARDS: ventilatory settings  and rescue therapies for refractory hypoxemia. Intensive care medicine 2016;42(5):699–711.  [PubMed: 27040102]  7. Weiss CH, McSparron JI, Chatterjee RS,",8,71,0.8480632305145264
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,CEIIUPPSARDS.pdf,"entered automatically for patients identified by the electronic health record as being eligible  for PP, then hospitals who admitted few eligible patients should be willing to support it (29). Alternatively, an integrated health system that also insures its beneficiaries might consider  all costs, including additional downstream costs of survivors, making the results of our  societal model more relevant. Suppose such a system was willing to pay $50,000 per QALY  gained and admitted 200 patients with moderate-severe ARDS annually.",6,47,0.8452279567718506
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,NBSARDS.pdf," how NMB agents are used in patients with ARDS. A very high proportion (96.6%) of intensivists who treat patients with moderate to severe ARDS use NMB, and almost 40% of these respondents use NMB in more than half their patients with moderate to severe ARDS. These results are in line with other recent surveys. The LUNG SAFE study, a prospective study of 459 ICUs in 50 countries conducted in the winter of 2014, found that 37",5,59,0.84464430809021
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,ROSE.pdf,"ade (ROSE) trial —  a multicenter, unblinded, randomized trial of  patients with moderate-to-severe ARDS — to  determine the efficacy and safety of early neuro- muscular blockade with concomitant heavy se- dation as compared with a strategy of usual  care with lighter sedation targets. We hypothe- sized that the use of early neuromuscular block- ade would result in lower all-cause in-hospital  mortality at 90 days",2,22,0.8434767723083496
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,ACURASYS.pdf," mechanical ventilation for the acute respiratory distress syn- drome (ARDS), neuromuscular blocking agents may improve oxygenation and de- crease ventilator-induced lung injury but may also cause muscle weakness. We evalu- ated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in  patients with early, severe ARDS. Methods In this multicenter, double-blind trial, 340 patients presenting to the intensive care  unit (ICU) with an onset",1,11,0.8382313251495361
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,CHEST.pdf,"High vs Low PEEP in Patients With ARDS Exhibiting Intense Inspiratory Effort During Assisted Ventilation A Randomized Crossover Trial Giuseppe Bello, MD; Valentina Giammatteo, MD; Alessandra Bisanti, MD; Luca Delle Cese, MD; Tommaso Rosà, MD; Luca S. Menga, MD; Luca Montini, MD; Teresa Michi, MD; Giorgia",1,1,0.8325238227844238
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,EDPMARDSLPMV.pdf," this result may be due to the wide range of VT used across the trials included. To try to answer this question, we investigated ΔPrs from two trials [4, 5] in which strict lung- protective mechanical ventilation, in particular 6 ml/kg predicted body weight VT, was applied to patients with ARDS. Our working hypothesis was that ΔPrs was asso- ciated with death, just like compliance (Crs) or Pplat,rs. Methods This is a",2,18,0.8322227001190186
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,CEIIUPPSARDS.pdf, Setting: Intensive care units that care for patients with ARDS. Subjects: Patients with moderate to severe ARDS. For reprints : Corresponding Author: Cameron M Baston. 3400 Spruce St. Philadelphia PA 19104. cbass@alum.mit.edu  +12159133239.  The work was performed at the University of Pennsylvania Declaration of Conflict of Interest: The authors have disclosed that they do not have any conflicts of interest. HHS Public Access Author manuscript Crit,1,6,0.8322227001190186
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,TOF-ARDS.pdf,"/kg of predicted body weight  (PBW) [2], a short course of neuromuscular blocking  agents (NMBAs) [3] in severely hypoxemic patients, and  the use of prone positioning (PP) [4]. NMBAs are fre- quently used in the most severe forms of ARDS [1]. They  are the only pharmacologic intervention that has been  shown to improve the prognosis of moderate-to-severe  ARDS",1,12,0.8279085159301758
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,NBSARDS.pdf,"13 and ROSE trials,26 moderate to severe ARDS in the survey was de- fined as PaO2/FIO2  150 mm Hg, along with other Berlin criteria. The survey was approved by the University of Maryland School of Medicine Institutional Review Board. The survey writing team generated an initial 16-ques- tion survey that included 6 demographic questions, 3 ques- tions about whether the respondent managed patients with ARDS and whether they used NMB in their management",2,22,0.8276324272155762
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,OSCILLATE.pdf,"DS.23-26 We therefore compared HFOV  with a conventional ventilation strategy that used  low tidal volumes and high levels of PEEP in pa- tients with new-onset, moderate-to-severe ARDS. Methods Study Oversight For the pilot phase of the study, we enrolled pa- tients at 11 centers in Canada and 1 in Saudi  Arabia from July 2007 through June 2008; for the  main trial, we enrolled patients at the same cen- ters",2,25,0.8250396251678467
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,BMIMSARDS.pdf,"ated Early (OSCILLATE) study was a randomized, controlled trial that randomized adults with moderate-to-severe ARDS to high-frequency oscillatory ventilation (HFOV) or conventional mechani- cal ventilation. The purpose of this sub-analysis of the OSCILLATE trial was to examine the association of BMI on mortality and relevant processes of care of subjects withmoderate-to-severeARDS.Wehypothesizedthatmor- tality differs across different BMI strata and",2,16,0.8244552612304688
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,BMIMSARDS.pdf," associations at both extremes of BMI. Conclusions In the OSCILLATE Trial, there was no difference in adjusted hospital mortality across all BMI strata in sub- jects with moderate-to-severe ARDS. Processes of care were not different between the BMI strata except for higher daily doses of fentanyl as BMI increased. ACKNOWLEDGMENTS We acknowledge Michael Chasse and Martin Albert for their critical review of the manuscript. REFERENCES 1. Ogden CL,",7,92,0.8244552612304688
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,BMIMSARDS.pdf,". It also includes subjects managed with HFOV, a group in which the relation of BMI and outcomes has not been studied before. Methods Study Subjects and Sample The OSCILLATE trial randomized 548 subjects with moderate-to-severe ARDS to HFOV or conventional ven- tilation from 39 ICUs in Canada, the United States, Saudi Arabia, Chile, and India.9 Institutional review boards of the participating centers approved the study. Patients were eligible for inclusion if they had",2,18,0.8244552612304688
32,Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?,PROSEVA.pdf," since no signifi- cant improvement was observed in patient survival  with prone positioning.7-10 However, meta-analy- ses2,11 have suggested that survival is significantly  improved with prone positioning as compared  with supine positioning among patients with se- verely hypoxemic ARDS at the time of random- ization. We conducted a prospective, multicenter,  randomized, controlled trial to explore whether  early application of prone positioning would im- prove survival among patients with",2,16,0.8239555358886719
33,Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??,THvsTN.pdf, initial publication. Explorative outcomes and results from the 24-month follow-up will be reported separately. Co-enrolment in the TAME trial The Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest: A Phase III Multi-Centre Randomized Controlled Trial (TAME trial) (NCT03114033) aims to determine whether targeted therapeutic mild hypercapnia improves neurological outcome at 6 months compared to standard care and targeted normocapnia.,6,82,0.9048099517822266
33,Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??,CETHACA.pdf," Stein- berger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statis- tics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25–e146. 4. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–556. 5. Bernard SA, Gray TW, Buist MD, Jones",7,93,0.800004243850708
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,SEPSISPAM.pdf," Surviving Sepsis Campaign recommends targeting a mean arterial pressure of  at least 65 mm Hg during initial resuscitation of patients with septic shock.  However, whether this blood-pressure target is more or less effective than a higher  target is unknown. Methods In a multicenter, open-label trial, we randomly assigned 776 patients with septic  shock to undergo resuscitation with a mean arterial pressure target of either 80 to  85 mm Hg (high-target group",1,9,0.8650882244110107
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,RIC.pdf," predictor of early mortality after cardiopulmonary resuscitation in cardiac arrest patients. Am J Emergency Med. 2012;30(9): 1804-1809.** 38. Gong P, Zhao H, Hua R, et al. Mild hypothermia inhibits systemic and cerebral complement activation in a swine model of cardiac arrest. J Cereb Blood Flow Metab. 2015;35(8):1289-1295.* 39. Kida K, Minamishima S, Wang",5,75,0.8615086078643799
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,THvsTN.pdf,"Background To date, targeted temperature management (TTM) is the only neuroprotective intervention after resuscitation from cardiac arrest that is recommended by guidelines. When studied in animals, interventions to lower the body temperature during cardiopulmonary arrest (intra-ische- mic cooling) appear to attenuate brain damage and improve survival.1,2 Cooling induced after the cardiac arrest (post-ischemic cooling) with a delayed onset might also be beneficial.3,4 In dogs, delayed",2,19,0.8612661361694336
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,RIC.pdf," predict increased mortality in patients resuscitated after out-of-hospital cardiac arrest. A post hoc sub-study of patients from the TTM-trial. PloS One. 2015; 10(3):e0120914.** 29. Annborn M, Dankiewicz J, Erlinge D, et al. Procalcitonin after cardiac arrest—an indicator of severity of illness, ischemia- reperfusion injury and outcome. Resuscitation. 2013;84",5,68,0.8583223819732666
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,BTCSCA.pdf," ClinicalTrials.gov number, NCT03141099.) ABSTR ACT Blood-Pressure Targets in Comatose  Survivors of Cardiac Arrest J. Kjaergaard, J.E. Møller, H. Schmidt, J. Grand, S. Mølstrøm, B. Borregaard,  S. Venø, L. Sarkisian, D. Mamaev, L.O. Jensen, B. Nyholm, D",1,11,0.8574154376983643
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,RIC.pdf,"58. Drabek T, Janata A, Wilson CD, et al. Minocycline attenuates brain tissue levels of TNF-alpha produced by neurons after pro- longed hypothermic cardiac arrest in rats. Resuscitation. 2014; 85(2):284-291.* 59. Wang QY, Sun P, Zhang Q, Yao SL. Minocycline attenuates microglial response and reduces neuronal death after cardiac arrest and cardiopulmonary resuscitation",6,90,0.8561689853668213
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,OHCA.pdf,"Review Out of hospital cardiac arrest: Past, present, and future Thomas Rea a, Peter J. Kudenchuk a, Michael R. Sayre b, Ann Doll c, Mickey Eisenberg b,* a Department of Medicine, University of Washington, United States b Department of Emergency Medicine, University of Washington, United States c Resuscitation Academy, United States Abstract Advances in resuscitation following out-of-hospital cardiac arrest (OHCA) provide an opportunity to improve public health",1,1,0.8541035652160645
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,RIC.pdf,"with cardiovascular dysfunction and vasopressor support in post-cardiac arrest patients. Resuscitation. 2017;121: 179-186.** 28. Johansson PI, Bro-Jeppesen J, Kjaergaard J, Wanscher M, Hassa- ger C, Ostrowski SR. Sympathoadrenal activation and endothelial damage are inter correlated and predict increased mortality in patients resuscitated after out-of-hospital cardiac arrest. A post hoc sub",5,67,0.8523764610290527
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,CAC.pdf,"Hearn N,  et al. Quality of cardiopulmonary resuscitation during in-hospital cardiac  arrest. JAMA 2005;293:305-10. 18.	 Berg RA, Sanders AB, Milander M, Tellez D, Liu P, Beyda D. Efficacy of  audio-prompted rate guidance in improving resuscitator performance of  cardiopulmonary resuscitation on children. Acad Emerg Med 1994;1:35-40",5,83,0.8498330116271973
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,RIC.pdf,"eng Y, Li E, Mu Q, et al. Hydrogen sulfide inhalation decreases early blood-brain barrier permeability and brain edema induced by cardiac arrest and resuscitation. J Cereb Blood Flow Metab. 2015;35:494-500.* 64. Wei X, Zhang B, Zhang Y, et al. Hydrogen sulfide inhalation improves neurological outcome via NF-kappaB-mediated inflammatory pathway in a rat model of cardiac arrest and resuscitation. Cell Phys",6,94,0.849268913269043
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,EXACT.pdf," out-of-hospital cardiac arrest using a rapid infusion of cold saline: the RINSE trial (rapid infusion of cold normal saline). Circulation 2016;134:797–805. 21. Wang HE, Prince DK, Drennan IR, et al. Post-resuscitation arterial oxygen and carbon dioxide and outcomes after out-of-hospital cardiac arrest. Resuscitation 2017;120:113–8. 22. Roberts BW, Kilgannon JH, Hunter",6,86,0.8463475704193115
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,EXACT.pdf," University of Western Australia, Australia j Warwick Medical School, University of Warwick, Coventry, United Kingdom Abstract Background: Experimental and observational research suggests hyperoxia following resuscitation from cardiac arrest is associated with neurological injury and worse clinical outcomes. This paper describes the rationale and design of the EXACT trial. EXACT aims to determine whether reducing oxygen in the acute phase of post-resuscitation care for out-of-hospital cardiac arrest (OHCA) improves survival. Methods: EXACT is a",1,4,0.8458786010742188
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,IHCA.pdf,", Tang F, Nallamothu BK, Girotra S, Perman SM,  et al. Long-term survival trends of medicare patients after in-hospital  cardiac arrest: insights from get with the guidelines-resuscitation(®).  Resuscitation. 2018;123:58–64. 	4.	 Andersson A, Arctaedius I, Cronberg T, Levin H, Nielsen N, Friberg H, et ",7,94,0.8357803821563721
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,IHCA.pdf," This  registry will hopefully stand alongside existing registries  to further our understanding of IHCA. Existing international registries such as the US  GWTG-R registry and the UK NCAA have provided data  that have informed and supported cardiac arrest guide- lines [22]. Furthermore, they have enabled us to under- stand how the incidence of cardiac arrest is influenced  by guidelines and medical advances [23]. Cardiac arrest  registries are a valuable resource enabling IHCA research  and",2,29,0.8294706344604492
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,MCAU.pdf," Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(suppl 2):S414-S435. 12. Gaspari R, Harvey J, DiCroce C, et al. Echocardiographic pre-pause imaging and identifying the acoustic window during CPR reduces CPR pause time during ACLS – a prospective cohort study. Resusc Plus. 2021;6:100094-100095. 13. Gottlieb M,",7,81,0.823448657989502
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,IHCA.pdf,"-​00505​60108​9b. 	9.	 Nolan JP, Soar J, Smith GB, Gwinnutt C, Parrott F, Power S, et al. Incidence  and outcome of in-hospital cardiac arrest in the United Kingdom  National Cardiac Arrest Audit. Resuscitation. 2014;85:987–92. 	10.	 Høybye M, Stankovic N, Holmberg M, Christensen HC,",7,99,0.823127031326294
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,THvsTN.pdf," damage indicate both benefit and harm.32,33 Theoretical rationale exists and currently hypothermia is the only clinical strategy aiming for neuroprotection for cardiac arrest victims. Specifically, in adults with cardiac arrest with shockable rhythms low quality evidence indicate benefit of 33°C and moderate quality evidence indicate no difference between 33°C and 36°C. The recent TTM1- trial has had a significant influence on the new ILCOR, AHA and ERC statements and guidelines for 2015,",7,92,0.8210816383361816
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,CETHACA.pdf,"Cost-Effectiveness of Therapeutic Hypothermia After Cardiac Arrest Raina M. Merchant, MD, MS; Lance B. Becker, MD; Benjamin S. Abella, MD, MPhil; David A. Asch, MD, MBA; Peter W. Groeneveld, MD, MS Background—Therapeutic hypothermia can improve survival and neurological outcomes in cardiac arrest survivors, but its cost-effectiveness is uncertain. We sought to evaluate the cost-effect",1,1,0.8195745944976807
34,Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?,MCAU.pdf,"��cient to indicate perfusion. Further data are needed to determine the most appropriate role of Doppler for pulse detection. Transesophageal Echocardiography Expert guidelines support a limited 3-view protocol for incorporating transesophageal echocardiography (TEE) into cardiac arrest management.125 Compared with TTE, placement of the TEE transducer directly into the esophagus provides continuous cardiac visualization during ongoing chest compressions and shortens pulse check",6,63,0.8190426826477051
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",EXACT.pdf," University of Western Australia, Australia j Warwick Medical School, University of Warwick, Coventry, United Kingdom Abstract Background: Experimental and observational research suggests hyperoxia following resuscitation from cardiac arrest is associated with neurological injury and worse clinical outcomes. This paper describes the rationale and design of the EXACT trial. EXACT aims to determine whether reducing oxygen in the acute phase of post-resuscitation care for out-of-hospital cardiac arrest (OHCA) improves survival. Methods: EXACT is a",1,4,0.8736124038696289
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",CETHACA.pdf," Heart Association recommended that comatose cardiac arrest survivors receive induced hypother- mia after ventricular fibrillation (VF) OHCA.7 Editorial see p 402 Despite these recommendations, use of therapeutic hypo- thermia remains limited.8,9 Recent estimates suggest that approximately 2300 (range 300 to 9500) additional comatose patients with cardiac arrest annually would achieve good neurological outcome if hypothermia was fully implemented in US hospitals.10 Diffusion of new treatments is often",1,9,0.8593087196350098
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",EXACT.pdf," patients had a SpO2 90%. These data suggested that oxygen titration post-ROSC is feasible in the prehospital environment, but needs to occur incrementally. Objectives and design This paper describes the rationale and design of the EXACT trial (acronym for Reduction of Oxygen After Cardiac Arrest). The EXACT trial is designed as a randomised, controlled, patient-blinded multi- centre trial with two parallel groups and a primary endpoint of survival to hospital",2,21,0.8509724140167236
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",CAC.pdf," M, Vanderhoek JY,  Fiskum G. Normoxic ventilation after cardiac arrest reduces oxidation of  brain lipids and improves neurological outcome. Stroke 1998;29:1679-86. 32.	 Zwemer CF, Whitesall SE, D’Alecy LG. Cardiopulmonary-cerebral  resuscitation with 100% oxygen exacerbates neurological dysfunction  following nine minutes of  normothermic cardiac arrest in dogs.  Resuscitation 1994",6,95,0.8474750518798828
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",HACA-LA.pdf,"20. Bernard SA, Jones BM. Treatment of comatose survivors of out-of- hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;7. 21. Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118–21. https:// doi.",7,100,0.8431241512298584
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",THvsTN.pdf,"Background To date, targeted temperature management (TTM) is the only neuroprotective intervention after resuscitation from cardiac arrest that is recommended by guidelines. When studied in animals, interventions to lower the body temperature during cardiopulmonary arrest (intra-ische- mic cooling) appear to attenuate brain damage and improve survival.1,2 Cooling induced after the cardiac arrest (post-ischemic cooling) with a delayed onset might also be beneficial.3,4 In dogs, delayed",2,19,0.8419246673583984
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",BTCSCA.pdf," ClinicalTrials.gov number, NCT03141099.) ABSTR ACT Blood-Pressure Targets in Comatose  Survivors of Cardiac Arrest J. Kjaergaard, J.E. Møller, H. Schmidt, J. Grand, S. Mølstrøm, B. Borregaard,  S. Venø, L. Sarkisian, D. Mamaev, L.O. Jensen, B. Nyholm, D",1,11,0.8414914608001709
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",CETHACA.pdf," (HACA) study group reported that therapeutic hypothermia improves survival and neurological outcomes in comatose resuscitated patients after OHCA.4,5 A subsequent meta-analysis demonstrated that an average of 6 (95% confidence interval 4 to 13) patients with OHCA needed to be treated with hypothermia for 1 additional patient to be discharged with good neurological outcome.6 In 2005 the American Heart Association recommended that comatose cardiac arrest survivors receive induced hypother- mia after ventricular",1,8,0.8406367301940918
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",EXACT.pdf," out-of-hospital cardiac arrest using a rapid infusion of cold saline: the RINSE trial (rapid infusion of cold normal saline). Circulation 2016;134:797–805. 21. Wang HE, Prince DK, Drennan IR, et al. Post-resuscitation arterial oxygen and carbon dioxide and outcomes after out-of-hospital cardiac arrest. Resuscitation 2017;120:113–8. 22. Roberts BW, Kilgannon JH, Hunter",6,86,0.8403737545013428
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",RIC.pdf,"eng Y, Li E, Mu Q, et al. Hydrogen sulfide inhalation decreases early blood-brain barrier permeability and brain edema induced by cardiac arrest and resuscitation. J Cereb Blood Flow Metab. 2015;35:494-500.* 64. Wei X, Zhang B, Zhang Y, et al. Hydrogen sulfide inhalation improves neurological outcome via NF-kappaB-mediated inflammatory pathway in a rat model of cardiac arrest and resuscitation. Cell Phys",6,94,0.8400633335113525
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",RIC.pdf,"58. Drabek T, Janata A, Wilson CD, et al. Minocycline attenuates brain tissue levels of TNF-alpha produced by neurons after pro- longed hypothermic cardiac arrest in rats. Resuscitation. 2014; 85(2):284-291.* 59. Wang QY, Sun P, Zhang Q, Yao SL. Minocycline attenuates microglial response and reduces neuronal death after cardiac arrest and cardiopulmonary resuscitation",6,90,0.8380064964294434
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",OHCA.pdf,"Review Out of hospital cardiac arrest: Past, present, and future Thomas Rea a, Peter J. Kudenchuk a, Michael R. Sayre b, Ann Doll c, Mickey Eisenberg b,* a Department of Medicine, University of Washington, United States b Department of Emergency Medicine, University of Washington, United States c Resuscitation Academy, United States Abstract Advances in resuscitation following out-of-hospital cardiac arrest (OHCA) provide an opportunity to improve public health",1,1,0.837902307510376
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",CETHACA.pdf,"Cost-Effectiveness of Therapeutic Hypothermia After Cardiac Arrest Raina M. Merchant, MD, MS; Lance B. Becker, MD; Benjamin S. Abella, MD, MPhil; David A. Asch, MD, MBA; Peter W. Groeneveld, MD, MS Background—Therapeutic hypothermia can improve survival and neurological outcomes in cardiac arrest survivors, but its cost-effectiveness is uncertain. We sought to evaluate the cost-effect",1,1,0.8351905345916748
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",RIC.pdf," predictor of early mortality after cardiopulmonary resuscitation in cardiac arrest patients. Am J Emergency Med. 2012;30(9): 1804-1809.** 38. Gong P, Zhao H, Hua R, et al. Mild hypothermia inhibits systemic and cerebral complement activation in a swine model of cardiac arrest. J Cereb Blood Flow Metab. 2015;35(8):1289-1295.* 39. Kida K, Minamishima S, Wang",5,75,0.8316473960876465
35,"Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?",EXACT.pdf," patient-blinded multi- centre trial with two parallel groups and a primary endpoint of survival to hospital discharge. The primary objective of EXACT is to determine whether reducing oxygen in the acute phase of post-resuscitation care for OHCA improves survival. Secondary objectives of the trial are to evaluate the effects of targeted oxygen on cardiac and neurological outcomes, and quality of life at 12-months (Table 1). Methods Trial summary The EXACT trial is funded in Australia by the National Health and Medical Research",2,22,0.830939531326294
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,RDSCI.pdf," Morimoto T, et al. Effect of dex- medetomidine on mortality and ventilator-free days in patients  requiring mechanical ventilation with sepsis: a randomized  clinical trial. JAMA. 2017;317:1321-1328. doi:10.1001/ jama.2017.2088 	 8.	 Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care  sedation predicts long-term mortality",5,64,0.9120891094207764
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf,"▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to prevent ICU delirium. Notable for being one of the few interventions shown  to prevent ICU delirium. 30. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and  ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmed",8,82,0.9120891094207764
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf," days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmedetomidine on mortality and ventilation in sepsis patients effect of  dexmedetomidine on mortality and ventilation in sepsis patients. JAMA 2017; 317:1321–1328.  [PubMed: 28322414]  31. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically",8,83,0.9098656177520752
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,SMDLTSWCI.pdf,"idine is becoming increasingly popular due to its  “cooperative sedation” and opioid-sparing  properties,  and the absence of respiratory depression. Neverthe- less, the SPICE III trial [28] reported that early use of  dexmedetomidine in mechanically ventilated patients  did not improve outcomes more than usual care. Most  Table 1  Baseline characteristics of patients in intention-to-treat analysis ICU, Intensive Care",6,68,0.8657300472259521
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,EDvsLSMENDS.pdf,"/2.0), which permits unrestricted use, distribution, and repro- duction in any medium, provided the original work is properly cited. Research Effect of dexmedetomidine versus lorazepam on  outcome in patients with sepsis: an a  priori-designed analysis of the MENDS randomized  controlled trial Pratik P Pandharipande1,2, Robert D Sanders*3, Timothy D Girard4,5,6, Stuart McGrane",1,2,0.8605594635009766
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,RDSCI.pdf," study showed that dexmedetomidine was  associated with lower prevalence of delirium relative to  midazolam (54% vs 76.6%, P < 0.01).3 However, preva- lence of delirium was similar between midazolam and dex- medetomidine in the MIDEX trial.4 In the PRODEX trial,  delirium occurred with greater frequency in the propofol  cohort compared with the dexmedet",4,46,0.8538122177124023
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf,"ard TD, et al. Effect of dexmedetomidine versus lorazepam on  outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized  controlled trial. Crit Care 2010; 14:R38. [PubMed: 20233428]  28. Reade MC, Eastwood GM, Bellomo R, et al. Effect of dexmedetomidine added to standard care on  ventilator-free time",8,79,0.852576494216919
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ESDDVCIP.pdf,"Intensive Care Med (2021) 47:455–466 https://doi.org/10.1007/s00134-021-06356-8 ORIGINAL Early sedation with dexmedetomidine  in ventilated critically ill patients  and heterogeneity of treatment effect in the  SPICE III randomised controlled trial Yahya Shehabi1,2*  , Ary Serpa Neto3,4,5,6",1,1,0.8487005233764648
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf,"22. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs Midazolam or propofol for  sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012;  307:1151–1160. [PubMed: 22436955]  23. Ruokonen E, Parviainen I, Jakob SM, et al. Dexmedetomidine versus propofol/midazol",8,75,0.8330981731414795
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,RDSCI.pdf," 	 4.	 Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine  vs midazolamor propofol for sedation during prolonged  mechanical ventilation: two randomized controlled trials.  JAMA. 2012;307:1151-1160. doi:10.1001/jama.2012.304 	 5.	 Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with",5,61,0.8282744884490967
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf," Jakob SM, et al. Dexmedetomidine versus propofol/midazolam for  long-term sedation during mechanical ventilation. Intensive Care Med 2009; 35:282–290.  [PubMed: 18795253]  24. Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically  ill adults: a prospective, multicenter study. Crit Care 2009; 13",8,76,0.8251018524169922
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,DDS.pdf,"2162–8. 8. Reeves RA, Boer WH, DeLeve L, Leenen FH. Nonselective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man. Clin Pharmacol Ther. 1984;35:461–6. 9. Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;",3,32,0.8236768245697021
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,DDS.pdf," a systematic review. Health Technol Assess. 2016;20:1–118. 11. Reade MC, Eastwood GM, Bellomo R, Bailey M, Bersten A, Cheung B, Davies A, Delaney A, Ghosh A, van Haren F, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA. 2016;315:",3,34,0.8233926296234131
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,ETSDMV.pdf,". Effect of dexmedetomidine added to standard care on  ventilator-free time in patients with agitated delirium: a randomized clinical trialdexmedetomidine  plus standard care in patients with agitated deliriumdexmedetomidine plus standard care in  patients with agitated delirium. JAMA 2016; 315:1460–1468. [PubMed: 26975647]  29. Skrobik Y, Duprey MS, Hill",8,80,0.8233926296234131
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,DDMLSMVICP.pdf,"Clinical Investigations Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients* Yahya Shehabi, FCICM, EMBA; Richard R. Riker, MD; Paula M. Bokesch, MD; Wayne Wisemandle, MA; Ayumi Shintani, PhD, MPH; E. Wesley Ely, MD, MPH; for the SEDCOM (Safety and Efﬁcacy of Dexmedetomidine Compared With",1,1,0.8197650909423828
36,Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?,SPICE-III.pdf,"- scribed level of sedation. More adverse events were reported in the dexmedetomi- dine group than in the usual-care group. (Funded by the National Health and  Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov  number, NCT01728558.) ABSTR ACT Early Sedation with Dexmedetomidine in  Critically Ill Patients Y. Shehabi, B.D. Howe, R. Bellomo, Y.",1,10,0.8163518905639648
